<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02453711</url>
  </required_header>
  <id_info>
    <org_study_id>NN9536-4153</org_study_id>
    <secondary_id>2014-001540-38</secondary_id>
    <secondary_id>U1111-1155-4660</secondary_id>
    <nct_id>NCT02453711</nct_id>
  </id_info>
  <brief_title>Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus</brief_title>
  <official_title>Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted globally. The aim of this trial is to investigate safety and efficacy
      of once-daily semaglutide in obese subjects without diabetes mellitus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">April 12, 2017</completion_date>
  <primary_completion_date type="Actual">March 30, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Change in Body Weight (%)</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Relative change from baseline (week 0) in body weight was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Weight Loss of ≥5% of Baseline Body Weight</measure>
    <time_frame>Week 52</time_frame>
    <description>Presented results are percentage of participants who lost more than or equal to 5% of their baseline (week 0) body weight at week 52. Analysis of observed in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using a binary logistic regression model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Weight Loss of ≥10% of Baseline Body Weight</measure>
    <time_frame>Week 52</time_frame>
    <description>Presented results are percentage of participants who lost more than or equal to 10% of their baseline (week 0) body weight at week 52. Analysis of observed in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using a binary logistic regression model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Weight (kg)</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in body weight was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist Circumference</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in waist circumference was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline waist circumference as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Waist to Hip Circumference Ratio</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in waist to hip circumference ratio was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline waist to hip circumference ratio as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BMI</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in body mass index (BMI) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline BMI as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline HbA1c as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline FPG as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Glycaemic Category (Normoglycaemia, Pre-diabetes, T2D)</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>The categorisation of glycaemic status as described in the protocol was not aligned with the usual diagnosis criteria which require repeated testing of blood glucose to confirm the diagnosis and allows for the diagnosis to be made based on random glucose assessments and/or 2-hour glucose assessments during an oral glucose tolerance test. Therefore, data were not collected for this outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SBP</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in systolic blood pressure (SBP) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline SBP as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DBP</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in diastolic blood pressure (DBP) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline DBP as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipids (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides and FFA)</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in lipids (total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, very low density lipoprotein (VLDL) cholesterol and triglycerides) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and respective baseline lipid value as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site. Free fatty acid (FFA) results are not presented as the values were considered invalid. The shipment of the samples to be tested for FFA was not as per the requirement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hsCRP</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Change from baseline (week 0) in high-sensitivity C-reactive protein (hsCRP) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline hsCRP as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IWQoL Lite</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>The planned analyses of the Impact of Weight on Quality of Life Lite (IWQoL-Lite) for Clinical Trials scores were not performed. The measure was still under development, and Novo Nordisk had not obtained a validated scoring of the instrument by the time of analysis of the trial results. Therefore, the total and subdomain scores on the IWQoL-Lite could not be provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Short Form-36 (SF-36) is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The 0-100 scale scores (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively of the 2009 U.S. general population. Change from baseline (week 0) in the domain scores and component summary (PCS and MCS) scores were evaluated at week 52. A positive change score indicates an improvement since baseline. Results are based on the in-trial observation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Change in Concomitant Medications (Antihypertensive and Lipid-lowering Medications)</measure>
    <time_frame>Week 0, Week 52</time_frame>
    <description>Participants' status on receiving concomitant medication (antihypertensive and lipid-lowering medications) at week 0 (yes/no) and week 52 (decreased, no change, increased or missing) are presented. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance With Nutritional Counselling</measure>
    <time_frame>Week 4-52</time_frame>
    <description>This outcome measure presents &quot;nutritional compliance results&quot; recorded at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52. Nutritional compliance was recorded on a 0 to 10 numeric rating scale (NRS), with higher scores representing better compliance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of AEs During the Trial</measure>
    <time_frame>Week 0-59</time_frame>
    <description>Adverse events (AEs) were recorded from week 0 to week 59. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hypoglycaemic Episodes During the Trial</measure>
    <time_frame>Week 0-59</time_frame>
    <description>Hypoglycaemic episodes were identified by either: 1) Subject reporting of symptoms of hypoglycaemia (low blood sugar) or 2) fasting plasma glucose (FPG) values ≤3.9 mmol/L (70 mg/dL) from blood sampling at site visits. Hypoglycaemic episodes were recorded from week 0 to week 59. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New and Ongoing Nausea, Vomiting, Diarrhoea, and Constipation Events by Week</measure>
    <time_frame>Week 0-59</time_frame>
    <description>Presented results are the number of nausea, vomiting, diarrhoea, and constipation events recorded from week 0 to week 59. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea: Individual Scores of Nausea Questionnaire and Severity by NRS Score</measure>
    <time_frame>Week 52</time_frame>
    <description>This outcome measure presents results recorded at week 52. If a participant experienced an event of nausea within 24 hours prior to a site visit, a nausea questionnaire had to be completed. Participants experiencing such events were to answer 5 different categories in the questionnaire ('duration of nausea', 'time from the latest injection of trial product to the onset of nausea', 'time from last food intake to the onset of nausea', 'nausea accompanied by vomiting (yes/no)' and 'severity of nausea (worst during episode)'). Severity of nausea was recorded on a 0 to 10 numeric rating scale (NRS), where 0 = 'No nausea' and 10 = 'Nausea as bad as it could be'. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in ECG</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Number of participants with electrocardiogram (ECG) results, &quot;normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)&quot; was recorded at baseline (week 0) and week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pulse</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in pulse rate was evaluated at week 52. Analysis of observed data using a mixed model for repeated measurements (MMRM) with treatment, region and sex as factors and baseline pulse as covariate, all nested within visit. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haematology: Haemoglobin</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in haemoglobin was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haematology: Haematocrit</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in haematocrit was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haematology: Thrombocytes, Leucocytes and Differential Count</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in haematological parameters, &quot;thrombocytes, leucocytes and differential cell count (eosinophils, neutrophils, basophils, monocytes and lymphocytes)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Haematology: Erythrocytes</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in erythrocytes was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemistry: Creatinine and Bilirubin (Total)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in biochemistry parameters, &quot;creatinine and bilirubin (total)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemistry: Creatinine Kinase, Amylase, Lipase, ALT, AST and ALP</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in biochemistry parameters, &quot;creatinine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemistry: Urea, Sodium, Potassium and Calcium (Total)</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in biochemistry parameters, &quot;urea, sodium, potassium and calcium (total)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemistry: Albumin</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in albumin was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemistry: Calcitonin</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in calcitonin was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Biochemistry: TSH</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Change from baseline (week 0) in thyroid stimulating hormone (TSH) was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mental Health Assessed by C-SSRS</measure>
    <time_frame>Week 0 and Week 4-59</time_frame>
    <description>Presented results are the number of participants with Columbia Suicidality Severity Rating Scale (C-SSRS) results recorded during baseline (week 0) and post baseline (week 4-52) visits. For classification of the events reported on the C-SSRS, the following categories were used: 1) Suicidal ideation, 2) Suicidal behaviour and 3) Non-suicidal self-injurious behaviour. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mental Health Assessed by PHQ-9</measure>
    <time_frame>Week 0, week 52</time_frame>
    <description>Patient health questionnaire-9 (PHQ-9) was recorded at baseline (week 0) and week 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. On the PHQ-9, the participant rates the frequency of 9 items on a scale from 0 (not at all) to 3 (nearly every day). The PHQ-9 total score ranges from 0−27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15−19 represent moderately severe depression and total scores of 20-27 represent severe depression. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-semaglutide Antibodies During and After Treatment</measure>
    <time_frame>Week 0-52</time_frame>
    <description>Participants were tested for anti-semaglutide antibodies from week 0 (post treatment) to week 52 (at weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52). This outcome measure is applicable only for the semaglutide treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>16</number_of_arms>
  <enrollment type="Actual">957</enrollment>
  <condition>Metabolism and Nutrition Disorder</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Sema 0.05 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0.05 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sema 0.1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0.05 or 0.1 mg with dose escalation every fourth week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sema 0.2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0.05, 0.1 or 0.2 mg with dose escalation every fourth week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sema 0.3 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every fourth week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sema 0.4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every fourth week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sema 0.3 mg (fast dose escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0.05, 0.1, 0.2 or 0.3 mg with dose escalation every second week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sema 0.4 mg (fast dose escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 0.05, 0.1, 0.2, 0.3, or 0.4 mg with dose escalation every second week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lira 3.0 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dose 0.6, 1.2, 1.8, 2.4, 3.0 mg with dose escalation every week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sema 0.05 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm matching active arm Sema 0.05 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sema 0.1 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm matching active arm Sema 0.1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sema 0.2 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm matching active arm Sema 0.2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sema 0.3 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm matching active arm Sema 0.3 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sema 0.4 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm matching active arm Sema 0.4 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sema 0.3 mg (fast dose escalation)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm matching active arm Sema 0.3 mg (fast dose escalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Sema 0.4 mg (fast dose escalation)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm matching active arm Sema 0.4 mg (fast dose escalation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Lira 3.0 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm matching active arm Lira 3.0 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.</description>
    <arm_group_label>Sema 0.05 mg</arm_group_label>
    <arm_group_label>Sema 0.1 mg</arm_group_label>
    <arm_group_label>Sema 0.2 mg</arm_group_label>
    <arm_group_label>Sema 0.3 mg</arm_group_label>
    <arm_group_label>Sema 0.3 mg (fast dose escalation)</arm_group_label>
    <arm_group_label>Sema 0.4 mg</arm_group_label>
    <arm_group_label>Sema 0.4 mg (fast dose escalation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.</description>
    <arm_group_label>Lira 3.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Once-daily subcutaneous (s.c., under the skin) administration.</description>
    <arm_group_label>Placebo Lira 3.0 mg</arm_group_label>
    <arm_group_label>Placebo Sema 0.05 mg</arm_group_label>
    <arm_group_label>Placebo Sema 0.1 mg</arm_group_label>
    <arm_group_label>Placebo Sema 0.2 mg</arm_group_label>
    <arm_group_label>Placebo Sema 0.3 mg</arm_group_label>
    <arm_group_label>Placebo Sema 0.3 mg (fast dose escalation)</arm_group_label>
    <arm_group_label>Placebo Sema 0.4 mg</arm_group_label>
    <arm_group_label>Placebo Sema 0.4 mg (fast dose escalation)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Informed consent obtained before any trial-related activities.
        Trial-related activities are any procedures that are carried out as part of the trial,
        including activities to determine suitability for the trial - Male or female, age 18 years
        or older at the time of signing inform consent - Body mass index (BMI) equal or above 30.0
        kg/m^2 at the screening visit - At least one unsuccessful weight loss attempt per
        investigator judgement Exclusion Criteria: - A HbA1c (glycosylated haemoglobin) equal to or
        above 6.5% at screening or diagnosed with type 1 or type 2 diabetes mellitus - Treatment
        with glucose lowering agent(s) within 90 days before screening - Screening calcitonin equal
        to or above 50 ng/L (pg/mL) - Personal or family history of medullary thyroid carcinoma or
        multiple endocrine neoplasia syndrome type 2 - History of pancreatitis (acute or chronic) -
        Obesity induced by endocrine disorders (e.g. Cushing Syndrome) - Treatment with any
        medication within 90 days before screening that based on investigator's judgement may cause
        significant weight change - Previous surgical treatment for obesity (liposuction and/or
        abdominoplasty performed 1 year before screening is allowed) - History of major depressive
        disorder within 2 years before randomisation - Any lifetime history of a suicidal attempt -
        Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing
        potential and not using an adequate contraceptive method (adequate contraceptive measures
        as required by local regulation or practice)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <zip>21075-6437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29651</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620-7352</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Merewether</city>
        <state>New South Wales</state>
        <zip>2291</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Heidelberg Heights</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mons</city>
        <zip>7000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2V 4J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3S 2N6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 1A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 1P2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4N 2W2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01219</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Duisburg</city>
        <zip>47051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint Ingbert-Oberwürzbach</city>
        <zip>66386</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <zip>70378</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49372</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>101990</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>109240</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tumen</city>
        <zip>625023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394018</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150003</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G31 2ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Luton</city>
        <zip>LU4 0DZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7TJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rotherham</city>
        <zip>S651DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <reference>
    <citation>Kolotkin RL, Williams VSL, Ervin CM, Williams N, Meincke HH, Qin S, von Huth Smith L, Fehnel SE. Validation of a new measure of quality of life in obesity trials: Impact of Weight on Quality of Life-Lite Clinical Trials Version. Clin Obes. 2019 Jun;9(3):e12310. doi: 10.1111/cob.12310. Epub 2019 Apr 16.</citation>
    <PMID>30993900</PMID>
  </reference>
  <results_reference>
    <citation>O'Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet. 2018 Aug 25;392(10148):637-649. doi: 10.1016/S0140-6736(18)31773-2. Epub 2018 Aug 16.</citation>
    <PMID>30122305</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2015</study_first_posted>
  <results_first_submitted>March 18, 2020</results_first_submitted>
  <results_first_submitted_qc>April 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 17, 2020</results_first_posted>
  <disposition_first_submitted>March 21, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>March 21, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 22, 2018</disposition_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Nutrition Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02453711/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/11/NCT02453711/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at 71 sites in 8 countries as follows: Australia: 5, Belgium: 5, Canada: 9, Germany: 6, Israel: 7, Russian Federation: 10, United Kingdom (UK):8, United States (US): 21. Along with this, recruitment of participants was planned at 3 sites (1 each in Germany, Russian Federation, and US), but where no participants were screened</recruitment_details>
      <pre_assignment_details>Design:Participants were randomised to 1 of the 16 parallel treatment arms in a 6:1 ratio (active:placebo) to receive either:A)Semaglutide 0.05/0.1/0.2/0.3/0.4 mg; dose escalation every 4th week B)Semaglutide 0.3/0.4 mg; dose escalation every second week C)Liraglutide 3.0 mg;dose escalation every week D)Placebo;matching each of the active treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Semaglutide 0.05 mg</title>
          <description>Participants received once daily semaglutide 0.05 mg subcutaneous (s.c.; under the skin) injections for 52 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Semaglutide 0.1 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
        </group>
        <group group_id="P3">
          <title>Semaglutide 0.2 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
        </group>
        <group group_id="P4">
          <title>Semaglutide 0.3 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
        </group>
        <group group_id="P5">
          <title>Semaglutide 0.4 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
        </group>
        <group group_id="P6">
          <title>Semaglutide 0.3 mg (Fast Escalation)</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
        </group>
        <group group_id="P7">
          <title>Semaglutide 0.4 mg (Fast Escalation)</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
        </group>
        <group group_id="P8">
          <title>Liraglutide 3.0 mg</title>
          <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
        </group>
        <group group_id="P9">
          <title>Placebo Pool</title>
          <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="103"/>
                <participants group_id="P5" count="102"/>
                <participants group_id="P6" count="102"/>
                <participants group_id="P7" count="103"/>
                <participants group_id="P8" count="103"/>
                <participants group_id="P9" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="103"/>
                <participants group_id="P5" count="102"/>
                <participants group_id="P6" count="102"/>
                <participants group_id="P7" count="103"/>
                <participants group_id="P8" count="103"/>
                <participants group_id="P9" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="103"/>
                <participants group_id="P4" count="103"/>
                <participants group_id="P5" count="102"/>
                <participants group_id="P6" count="102"/>
                <participants group_id="P7" count="103"/>
                <participants group_id="P8" count="103"/>
                <participants group_id="P9" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="96"/>
                <participants group_id="P5" count="100"/>
                <participants group_id="P6" count="96"/>
                <participants group_id="P7" count="100"/>
                <participants group_id="P8" count="96"/>
                <participants group_id="P9" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="7"/>
                <participants group_id="P9" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unclassified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall number of baseline participants = full analysis set (FAS) which included all randomised participants. Number Analyzed = number of participants with available data.</population>
      <group_list>
        <group group_id="B1">
          <title>Semaglutide 0.05 mg</title>
          <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Semaglutide 0.1 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
        </group>
        <group group_id="B3">
          <title>Semaglutide 0.2 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
        </group>
        <group group_id="B4">
          <title>Semaglutide 0.3 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
        </group>
        <group group_id="B5">
          <title>Semaglutide 0.4 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
        </group>
        <group group_id="B6">
          <title>Semaglutide 0.3 mg (Fast Escalation)</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
        </group>
        <group group_id="B7">
          <title>Semaglutide 0.4 mg (Fast Escalation)</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
        </group>
        <group group_id="B8">
          <title>Liraglutide 3.0 mg</title>
          <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
        </group>
        <group group_id="B9">
          <title>Placebo Pool</title>
          <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="103"/>
            <count group_id="B4" value="103"/>
            <count group_id="B5" value="102"/>
            <count group_id="B6" value="102"/>
            <count group_id="B7" value="103"/>
            <count group_id="B8" value="103"/>
            <count group_id="B9" value="136"/>
            <count group_id="B10" value="957"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="102"/>
                    <count group_id="B3" value="103"/>
                    <count group_id="B4" value="103"/>
                    <count group_id="B5" value="102"/>
                    <count group_id="B6" value="102"/>
                    <count group_id="B7" value="103"/>
                    <count group_id="B8" value="103"/>
                    <count group_id="B9" value="136"/>
                    <count group_id="B10" value="957"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.97" spread="12.80"/>
                    <measurement group_id="B2" value="45.24" spread="12.62"/>
                    <measurement group_id="B3" value="44.37" spread="11.24"/>
                    <measurement group_id="B4" value="46.73" spread="12.02"/>
                    <measurement group_id="B5" value="48.37" spread="13.44"/>
                    <measurement group_id="B6" value="47.10" spread="12.05"/>
                    <measurement group_id="B7" value="46.07" spread="13.51"/>
                    <measurement group_id="B8" value="48.50" spread="11.22"/>
                    <measurement group_id="B9" value="46.42" spread="12.80"/>
                    <measurement group_id="B10" value="46.63" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="102"/>
                    <count group_id="B3" value="103"/>
                    <count group_id="B4" value="103"/>
                    <count group_id="B5" value="102"/>
                    <count group_id="B6" value="102"/>
                    <count group_id="B7" value="103"/>
                    <count group_id="B8" value="103"/>
                    <count group_id="B9" value="136"/>
                    <count group_id="B10" value="957"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="66"/>
                    <measurement group_id="B7" value="67"/>
                    <measurement group_id="B8" value="67"/>
                    <measurement group_id="B9" value="88"/>
                    <measurement group_id="B10" value="619"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="36"/>
                    <measurement group_id="B7" value="36"/>
                    <measurement group_id="B8" value="36"/>
                    <measurement group_id="B9" value="48"/>
                    <measurement group_id="B10" value="338"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="102"/>
                    <count group_id="B3" value="103"/>
                    <count group_id="B4" value="103"/>
                    <count group_id="B5" value="102"/>
                    <count group_id="B6" value="102"/>
                    <count group_id="B7" value="103"/>
                    <count group_id="B8" value="103"/>
                    <count group_id="B9" value="136"/>
                    <count group_id="B10" value="957"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="71"/>
                    <measurement group_id="B6" value="76"/>
                    <measurement group_id="B7" value="68"/>
                    <measurement group_id="B8" value="78"/>
                    <measurement group_id="B9" value="97"/>
                    <measurement group_id="B10" value="700"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="22"/>
                    <measurement group_id="B7" value="25"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="24"/>
                    <measurement group_id="B10" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="102"/>
                    <count group_id="B3" value="103"/>
                    <count group_id="B4" value="103"/>
                    <count group_id="B5" value="102"/>
                    <count group_id="B6" value="102"/>
                    <count group_id="B7" value="103"/>
                    <count group_id="B8" value="103"/>
                    <count group_id="B9" value="136"/>
                    <count group_id="B10" value="957"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="7"/>
                    <measurement group_id="B10" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="90"/>
                    <measurement group_id="B6" value="82"/>
                    <measurement group_id="B7" value="91"/>
                    <measurement group_id="B8" value="93"/>
                    <measurement group_id="B9" value="117"/>
                    <measurement group_id="B10" value="827"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not applicable</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="9"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>Kilogram (Kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="102"/>
                    <count group_id="B3" value="103"/>
                    <count group_id="B4" value="103"/>
                    <count group_id="B5" value="102"/>
                    <count group_id="B6" value="102"/>
                    <count group_id="B7" value="103"/>
                    <count group_id="B8" value="103"/>
                    <count group_id="B9" value="136"/>
                    <count group_id="B10" value="957"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="111.29" spread="23.17"/>
                    <measurement group_id="B2" value="111.31" spread="21.47"/>
                    <measurement group_id="B3" value="114.49" spread="24.53"/>
                    <measurement group_id="B4" value="111.51" spread="22.96"/>
                    <measurement group_id="B5" value="113.20" spread="26.42"/>
                    <measurement group_id="B6" value="108.11" spread="22.08"/>
                    <measurement group_id="B7" value="109.56" spread="21.33"/>
                    <measurement group_id="B8" value="108.71" spread="21.94"/>
                    <measurement group_id="B9" value="114.19" spread="25.37"/>
                    <measurement group_id="B10" value="111.48" spread="23.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated haemoglobin (HbA1c)</title>
          <population>Number Analyzed = number of participants in the FAS with available data. FAS included all randomised participants.</population>
          <units>Percentage (%) of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="101"/>
                    <count group_id="B3" value="103"/>
                    <count group_id="B4" value="103"/>
                    <count group_id="B5" value="102"/>
                    <count group_id="B6" value="102"/>
                    <count group_id="B7" value="103"/>
                    <count group_id="B8" value="103"/>
                    <count group_id="B9" value="136"/>
                    <count group_id="B10" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.51" spread="0.35"/>
                    <measurement group_id="B2" value="5.45" spread="0.43"/>
                    <measurement group_id="B3" value="5.41" spread="0.39"/>
                    <measurement group_id="B4" value="5.51" spread="0.38"/>
                    <measurement group_id="B5" value="5.47" spread="0.42"/>
                    <measurement group_id="B6" value="5.48" spread="0.41"/>
                    <measurement group_id="B7" value="5.49" spread="0.42"/>
                    <measurement group_id="B8" value="5.53" spread="0.38"/>
                    <measurement group_id="B9" value="5.54" spread="0.38"/>
                    <measurement group_id="B10" value="5.49" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting plasma glucose (FPG)</title>
          <population>Number Analyzed = number of participants in the FAS with available data. FAS included all randomised participants.</population>
          <units>Millimoles per litre (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="103"/>
                    <count group_id="B2" value="102"/>
                    <count group_id="B3" value="103"/>
                    <count group_id="B4" value="103"/>
                    <count group_id="B5" value="101"/>
                    <count group_id="B6" value="102"/>
                    <count group_id="B7" value="103"/>
                    <count group_id="B8" value="103"/>
                    <count group_id="B9" value="136"/>
                    <count group_id="B10" value="956"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.48" spread="0.64"/>
                    <measurement group_id="B2" value="5.48" spread="0.55"/>
                    <measurement group_id="B3" value="5.41" spread="0.77"/>
                    <measurement group_id="B4" value="5.48" spread="0.73"/>
                    <measurement group_id="B5" value="5.40" spread="0.67"/>
                    <measurement group_id="B6" value="5.43" spread="0.64"/>
                    <measurement group_id="B7" value="5.54" spread="0.87"/>
                    <measurement group_id="B8" value="5.55" spread="0.73"/>
                    <measurement group_id="B9" value="5.50" spread="0.62"/>
                    <measurement group_id="B10" value="5.48" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Change in Body Weight (%)</title>
        <description>Relative change from baseline (week 0) in body weight was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Body Weight (%)</title>
          <description>Relative change from baseline (week 0) in body weight was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Percentage (%) of body weight</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="95"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="100"/>
                <count group_id="O8" value="96"/>
                <count group_id="O9" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.99" spread="0.85"/>
                    <measurement group_id="O2" value="-8.62" spread="0.84"/>
                    <measurement group_id="O3" value="-11.60" spread="0.85"/>
                    <measurement group_id="O4" value="-11.17" spread="0.85"/>
                    <measurement group_id="O5" value="-13.84" spread="0.83"/>
                    <measurement group_id="O6" value="-11.38" spread="0.85"/>
                    <measurement group_id="O7" value="-16.29" spread="0.83"/>
                    <measurement group_id="O8" value="-7.76" spread="0.85"/>
                    <measurement group_id="O9" value="-2.29" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett’s method was used to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>=0.0055</p_value>
            <method>ANCOVA</method>
            <param_type>Treatment difference (%-points)</param_type>
            <param_value>-3.70</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.13</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.55</ci_lower_limit>
            <ci_upper_limit>-0.85</ci_upper_limit>
            <estimate_desc>Semaglutide 0.05 mg - placebo pool</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett’s method was used to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Treatment difference (%-points)</param_type>
            <param_value>-6.32</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.16</ci_lower_limit>
            <ci_upper_limit>-3.49</ci_upper_limit>
            <estimate_desc>Semaglutide 0.1 mg - placebo pool</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett’s method was used to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Treatment difference (%-points)</param_type>
            <param_value>-9.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.15</ci_lower_limit>
            <ci_upper_limit>-6.46</ci_upper_limit>
            <estimate_desc>Semaglutide 0.2 mg - placebo pool</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett’s method was used to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Treatment difference (%-points)</param_type>
            <param_value>-8.88</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.72</ci_lower_limit>
            <ci_upper_limit>-6.03</ci_upper_limit>
            <estimate_desc>Semaglutide 0.3 mg - placebo pool</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O9</group_id>
            </group_id_list>
            <groups_desc>J2R-MI: Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Dunnett’s method was used to adjust for multiple comparisons.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Treatment difference (%-points)</param_type>
            <param_value>-11.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.12</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.38</ci_lower_limit>
            <ci_upper_limit>-8.72</ci_upper_limit>
            <estimate_desc>Semaglutide 0.4 mg - placebo pool</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Weight Loss of ≥5% of Baseline Body Weight</title>
        <description>Presented results are percentage of participants who lost more than or equal to 5% of their baseline (week 0) body weight at week 52. Analysis of observed in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using a binary logistic regression model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Weight Loss of ≥5% of Baseline Body Weight</title>
          <description>Presented results are percentage of participants who lost more than or equal to 5% of their baseline (week 0) body weight at week 52. Analysis of observed in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using a binary logistic regression model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Percentage (%) of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="95"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="100"/>
                <count group_id="O8" value="96"/>
                <count group_id="O9" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.50"/>
                    <measurement group_id="O2" value="67.49"/>
                    <measurement group_id="O3" value="74.91"/>
                    <measurement group_id="O4" value="80.52"/>
                    <measurement group_id="O5" value="82.52"/>
                    <measurement group_id="O6" value="72.19"/>
                    <measurement group_id="O7" value="89.58"/>
                    <measurement group_id="O8" value="66.12"/>
                    <measurement group_id="O9" value="22.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Weight Loss of ≥10% of Baseline Body Weight</title>
        <description>Presented results are percentage of participants who lost more than or equal to 10% of their baseline (week 0) body weight at week 52. Analysis of observed in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using a binary logistic regression model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Weight Loss of ≥10% of Baseline Body Weight</title>
          <description>Presented results are percentage of participants who lost more than or equal to 10% of their baseline (week 0) body weight at week 52. Analysis of observed in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using a binary logistic regression model with treatment, region and sex as factors and baseline body weight as covariate. In-trial observation period was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Percentage (%) of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="95"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="100"/>
                <count group_id="O8" value="96"/>
                <count group_id="O9" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.94"/>
                    <measurement group_id="O2" value="36.57"/>
                    <measurement group_id="O3" value="55.95"/>
                    <measurement group_id="O4" value="57.76"/>
                    <measurement group_id="O5" value="64.61"/>
                    <measurement group_id="O6" value="58.45"/>
                    <measurement group_id="O7" value="71.91"/>
                    <measurement group_id="O8" value="33.98"/>
                    <measurement group_id="O9" value="10.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Body Weight (kg)</title>
        <description>Change from baseline (week 0) in body weight was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Weight (kg)</title>
          <description>Change from baseline (week 0) in body weight was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline body weight as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Kilogram (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="95"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="100"/>
                <count group_id="O8" value="96"/>
                <count group_id="O9" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.66" spread="0.94"/>
                    <measurement group_id="O2" value="-9.34" spread="0.93"/>
                    <measurement group_id="O3" value="-12.30" spread="0.93"/>
                    <measurement group_id="O4" value="-12.45" spread="0.93"/>
                    <measurement group_id="O5" value="-15.15" spread="0.92"/>
                    <measurement group_id="O6" value="-12.54" spread="0.93"/>
                    <measurement group_id="O7" value="-17.36" spread="0.92"/>
                    <measurement group_id="O8" value="-8.47" spread="0.93"/>
                    <measurement group_id="O9" value="-2.48" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist Circumference</title>
        <description>Change from baseline (week 0) in waist circumference was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline waist circumference as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist Circumference</title>
          <description>Change from baseline (week 0) in waist circumference was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline waist circumference as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Centimetre (cm)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="82"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="91"/>
                <count group_id="O8" value="86"/>
                <count group_id="O9" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.11" spread="0.93"/>
                    <measurement group_id="O2" value="-8.75" spread="0.90"/>
                    <measurement group_id="O3" value="-11.02" spread="0.89"/>
                    <measurement group_id="O4" value="-10.91" spread="0.89"/>
                    <measurement group_id="O5" value="-12.31" spread="0.91"/>
                    <measurement group_id="O6" value="-11.06" spread="0.95"/>
                    <measurement group_id="O7" value="-14.88" spread="0.88"/>
                    <measurement group_id="O8" value="-8.35" spread="0.89"/>
                    <measurement group_id="O9" value="-3.47" spread="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Waist to Hip Circumference Ratio</title>
        <description>Change from baseline (week 0) in waist to hip circumference ratio was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline waist to hip circumference ratio as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Waist to Hip Circumference Ratio</title>
          <description>Change from baseline (week 0) in waist to hip circumference ratio was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline waist to hip circumference ratio as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Waist to hip circumference ratio</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="82"/>
                <count group_id="O6" value="73"/>
                <count group_id="O7" value="91"/>
                <count group_id="O8" value="86"/>
                <count group_id="O9" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.01"/>
                    <measurement group_id="O2" value="-0.02" spread="0.01"/>
                    <measurement group_id="O3" value="-0.02" spread="0.01"/>
                    <measurement group_id="O4" value="-0.03" spread="0.01"/>
                    <measurement group_id="O5" value="-0.02" spread="0.01"/>
                    <measurement group_id="O6" value="-0.02" spread="0.01"/>
                    <measurement group_id="O7" value="-0.03" spread="0.01"/>
                    <measurement group_id="O8" value="-0.02" spread="0.01"/>
                    <measurement group_id="O9" value="-0.01" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in BMI</title>
        <description>Change from baseline (week 0) in body mass index (BMI) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline BMI as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in BMI</title>
          <description>Change from baseline (week 0) in body mass index (BMI) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline BMI as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Kilogram per square meter (kg/m^2)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="95"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="100"/>
                <count group_id="O8" value="96"/>
                <count group_id="O9" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.37" spread="0.33"/>
                    <measurement group_id="O2" value="-3.36" spread="0.33"/>
                    <measurement group_id="O3" value="-4.38" spread="0.33"/>
                    <measurement group_id="O4" value="-4.40" spread="0.33"/>
                    <measurement group_id="O5" value="-5.40" spread="0.33"/>
                    <measurement group_id="O6" value="-4.48" spread="0.33"/>
                    <measurement group_id="O7" value="-6.21" spread="0.33"/>
                    <measurement group_id="O8" value="-3.03" spread="0.33"/>
                    <measurement group_id="O9" value="-0.88" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in HbA1c</title>
        <description>Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline HbA1c as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in HbA1c</title>
          <description>Change from baseline (week 0) in glycosylated haemoglobin (HbA1c) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline HbA1c as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Percentage of HbA1c</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="87"/>
                <count group_id="O5" value="82"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="91"/>
                <count group_id="O8" value="85"/>
                <count group_id="O9" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.03"/>
                    <measurement group_id="O2" value="-0.21" spread="0.03"/>
                    <measurement group_id="O3" value="-0.28" spread="0.03"/>
                    <measurement group_id="O4" value="-0.23" spread="0.03"/>
                    <measurement group_id="O5" value="-0.29" spread="0.03"/>
                    <measurement group_id="O6" value="-0.25" spread="0.03"/>
                    <measurement group_id="O7" value="-0.34" spread="0.03"/>
                    <measurement group_id="O8" value="-0.21" spread="0.03"/>
                    <measurement group_id="O9" value="-0.01" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in FPG</title>
        <description>Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline FPG as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in FPG</title>
          <description>Change from baseline (week 0) in fasting plasma glucose (FPG) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline FPG as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Millimoles per litre (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="81"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="91"/>
                <count group_id="O8" value="86"/>
                <count group_id="O9" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.06"/>
                    <measurement group_id="O2" value="-0.35" spread="0.06"/>
                    <measurement group_id="O3" value="-0.40" spread="0.06"/>
                    <measurement group_id="O4" value="-0.39" spread="0.06"/>
                    <measurement group_id="O5" value="-0.43" spread="0.06"/>
                    <measurement group_id="O6" value="-0.38" spread="0.06"/>
                    <measurement group_id="O7" value="-0.51" spread="0.06"/>
                    <measurement group_id="O8" value="-0.35" spread="0.06"/>
                    <measurement group_id="O9" value="0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glycaemic Category (Normoglycaemia, Pre-diabetes, T2D)</title>
        <description>The categorisation of glycaemic status as described in the protocol was not aligned with the usual diagnosis criteria which require repeated testing of blood glucose to confirm the diagnosis and allows for the diagnosis to be made based on random glucose assessments and/or 2-hour glucose assessments during an oral glucose tolerance test. Therefore, data were not collected for this outcome measure.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Data were not collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycaemic Category (Normoglycaemia, Pre-diabetes, T2D)</title>
          <description>The categorisation of glycaemic status as described in the protocol was not aligned with the usual diagnosis criteria which require repeated testing of blood glucose to confirm the diagnosis and allows for the diagnosis to be made based on random glucose assessments and/or 2-hour glucose assessments during an oral glucose tolerance test. Therefore, data were not collected for this outcome measure.</description>
          <population>Data were not collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SBP</title>
        <description>Change from baseline (week 0) in systolic blood pressure (SBP) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline SBP as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SBP</title>
          <description>Change from baseline (week 0) in systolic blood pressure (SBP) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline SBP as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="95"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="100"/>
                <count group_id="O8" value="96"/>
                <count group_id="O9" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.46" spread="1.20"/>
                    <measurement group_id="O2" value="-5.76" spread="1.18"/>
                    <measurement group_id="O3" value="-6.26" spread="1.19"/>
                    <measurement group_id="O4" value="-6.41" spread="1.19"/>
                    <measurement group_id="O5" value="-5.81" spread="1.16"/>
                    <measurement group_id="O6" value="-6.07" spread="1.19"/>
                    <measurement group_id="O7" value="-10.26" spread="1.16"/>
                    <measurement group_id="O8" value="-5.45" spread="1.18"/>
                    <measurement group_id="O9" value="-1.58" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in DBP</title>
        <description>Change from baseline (week 0) in diastolic blood pressure (DBP) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline DBP as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in DBP</title>
          <description>Change from baseline (week 0) in diastolic blood pressure (DBP) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline DBP as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="96"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="95"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="95"/>
                <count group_id="O7" value="100"/>
                <count group_id="O8" value="96"/>
                <count group_id="O9" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" spread="0.84"/>
                    <measurement group_id="O2" value="-2.65" spread="0.82"/>
                    <measurement group_id="O3" value="-4.09" spread="0.83"/>
                    <measurement group_id="O4" value="-2.98" spread="0.83"/>
                    <measurement group_id="O5" value="-3.61" spread="0.80"/>
                    <measurement group_id="O6" value="-2.20" spread="0.83"/>
                    <measurement group_id="O7" value="-5.52" spread="0.80"/>
                    <measurement group_id="O8" value="-2.70" spread="0.82"/>
                    <measurement group_id="O9" value="-1.50" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipids (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides and FFA)</title>
        <description>Change from baseline (week 0) in lipids (total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, very low density lipoprotein (VLDL) cholesterol and triglycerides) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and respective baseline lipid value as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site. Free fatty acid (FFA) results are not presented as the values were considered invalid. The shipment of the samples to be tested for FFA was not as per the requirement.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = FAS which included all randomised participants. Number Analyzed = number of participants in the FAS who contributed to the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipids (Total Cholesterol, LDL Cholesterol, HDL Cholesterol, VLDL Cholesterol, Triglycerides and FFA)</title>
          <description>Change from baseline (week 0) in lipids (total cholesterol, low density lipoprotein (LDL) cholesterol, high density lipoprotein (HDL) cholesterol, very low density lipoprotein (VLDL) cholesterol and triglycerides) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and respective baseline lipid value as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site. Free fatty acid (FFA) results are not presented as the values were considered invalid. The shipment of the samples to be tested for FFA was not as per the requirement.</description>
          <population>Overall number of participants analyzed = FAS which included all randomised participants. Number Analyzed = number of participants in the FAS who contributed to the analysis.</population>
          <units>Millimoles per litre (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="74"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="85"/>
                    <count group_id="O9" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.02"/>
                    <measurement group_id="O2" value="0.95" spread="0.01"/>
                    <measurement group_id="O3" value="0.93" spread="0.01"/>
                    <measurement group_id="O4" value="0.93" spread="0.01"/>
                    <measurement group_id="O5" value="0.93" spread="0.01"/>
                    <measurement group_id="O6" value="0.93" spread="0.02"/>
                    <measurement group_id="O7" value="0.92" spread="0.01"/>
                    <measurement group_id="O8" value="0.96" spread="0.01"/>
                    <measurement group_id="O9" value="0.97" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="85"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="89"/>
                    <count group_id="O8" value="82"/>
                    <count group_id="O9" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.02"/>
                    <measurement group_id="O2" value="0.93" spread="0.02"/>
                    <measurement group_id="O3" value="0.93" spread="0.02"/>
                    <measurement group_id="O4" value="0.92" spread="0.02"/>
                    <measurement group_id="O5" value="0.93" spread="0.02"/>
                    <measurement group_id="O6" value="0.92" spread="0.02"/>
                    <measurement group_id="O7" value="0.91" spread="0.02"/>
                    <measurement group_id="O8" value="0.95" spread="0.02"/>
                    <measurement group_id="O9" value="0.97" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="74"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="85"/>
                    <count group_id="O9" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="0.01"/>
                    <measurement group_id="O2" value="1.02" spread="0.01"/>
                    <measurement group_id="O3" value="1.02" spread="0.01"/>
                    <measurement group_id="O4" value="1.02" spread="0.01"/>
                    <measurement group_id="O5" value="1.00" spread="0.01"/>
                    <measurement group_id="O6" value="1.00" spread="0.02"/>
                    <measurement group_id="O7" value="1.01" spread="0.01"/>
                    <measurement group_id="O8" value="1.00" spread="0.01"/>
                    <measurement group_id="O9" value="1.00" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VLDL cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.90" spread="0.03"/>
                    <measurement group_id="O2" value="0.89" spread="0.03"/>
                    <measurement group_id="O3" value="0.81" spread="0.03"/>
                    <measurement group_id="O4" value="0.85" spread="0.03"/>
                    <measurement group_id="O5" value="0.81" spread="0.03"/>
                    <measurement group_id="O6" value="0.87" spread="0.04"/>
                    <measurement group_id="O7" value="0.81" spread="0.03"/>
                    <measurement group_id="O8" value="0.91" spread="0.03"/>
                    <measurement group_id="O9" value="0.95" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="72"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="0.04"/>
                    <measurement group_id="O2" value="0.88" spread="0.03"/>
                    <measurement group_id="O3" value="0.81" spread="0.03"/>
                    <measurement group_id="O4" value="0.85" spread="0.03"/>
                    <measurement group_id="O5" value="0.80" spread="0.03"/>
                    <measurement group_id="O6" value="0.87" spread="0.04"/>
                    <measurement group_id="O7" value="0.80" spread="0.03"/>
                    <measurement group_id="O8" value="0.90" spread="0.03"/>
                    <measurement group_id="O9" value="0.95" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in hsCRP</title>
        <description>Change from baseline (week 0) in high-sensitivity C-reactive protein (hsCRP) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline hsCRP as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in hsCRP</title>
          <description>Change from baseline (week 0) in high-sensitivity C-reactive protein (hsCRP) was evaluated at week 52. Analysis of in-trial data with missing observations imputed from the pooled placebo arms based on a jump to reference multiple (x1000) imputation (J2R-MI) approach. Week 52 responses were analysed using an analysis of covariance model with treatment, region and sex as factors and baseline hsCRP as covariate. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Milligrams per decilitre (mg/dL)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="87"/>
                <count group_id="O5" value="82"/>
                <count group_id="O6" value="74"/>
                <count group_id="O7" value="91"/>
                <count group_id="O8" value="85"/>
                <count group_id="O9" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.07"/>
                    <measurement group_id="O2" value="0.65" spread="0.06"/>
                    <measurement group_id="O3" value="0.57" spread="0.05"/>
                    <measurement group_id="O4" value="0.66" spread="0.06"/>
                    <measurement group_id="O5" value="0.54" spread="0.05"/>
                    <measurement group_id="O6" value="0.58" spread="0.05"/>
                    <measurement group_id="O7" value="0.44" spread="0.04"/>
                    <measurement group_id="O8" value="0.72" spread="0.06"/>
                    <measurement group_id="O9" value="0.82" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in IWQoL Lite</title>
        <description>The planned analyses of the Impact of Weight on Quality of Life Lite (IWQoL-Lite) for Clinical Trials scores were not performed. The measure was still under development, and Novo Nordisk had not obtained a validated scoring of the instrument by the time of analysis of the trial results. Therefore, the total and subdomain scores on the IWQoL-Lite could not be provided.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>This outcome measure was not analysed.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in IWQoL Lite</title>
          <description>The planned analyses of the Impact of Weight on Quality of Life Lite (IWQoL-Lite) for Clinical Trials scores were not performed. The measure was still under development, and Novo Nordisk had not obtained a validated scoring of the instrument by the time of analysis of the trial results. Therefore, the total and subdomain scores on the IWQoL-Lite could not be provided.</description>
          <population>This outcome measure was not analysed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in SF-36</title>
        <description>Short Form-36 (SF-36) is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The 0-100 scale scores (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively of the 2009 U.S. general population. Change from baseline (week 0) in the domain scores and component summary (PCS and MCS) scores were evaluated at week 52. A positive change score indicates an improvement since baseline. Results are based on the in-trial observation period.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in SF-36</title>
          <description>Short Form-36 (SF-36) is a 36-item patient-reported survey of patient health that measures the participant's overall health-related quality of life (HRQoL). SF-36v2™ (acute version) questionnaire measured eight domains of functional health and well-being as well as two component summary scores (physical component summary (PCS) and mental component summary (MCS)). The 0-100 scale scores (where higher scores indicated a better HRQoL) from the SF-36 were converted to norm-based scores to enable a direct interpretation in relation to the distribution of the scores in the 2009 U.S. general population. In the metric of norm-based scores, 50 and 10 corresponds to the mean and standard deviation respectively of the 2009 U.S. general population. Change from baseline (week 0) in the domain scores and component summary (PCS and MCS) scores were evaluated at week 52. A positive change score indicates an improvement since baseline. Results are based on the in-trial observation period.</description>
          <population>Overall number of participants analyzed = number of participants in the FAS who contributed to the analysis. FAS included all randomised participants.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="22"/>
                <count group_id="O7" value="24"/>
                <count group_id="O8" value="31"/>
                <count group_id="O9" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bodily pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.85" spread="10.99"/>
                    <measurement group_id="O2" value="3.01" spread="6.41"/>
                    <measurement group_id="O3" value="4.27" spread="7.14"/>
                    <measurement group_id="O4" value="3.82" spread="7.11"/>
                    <measurement group_id="O5" value="5.16" spread="8.02"/>
                    <measurement group_id="O6" value="1.88" spread="9.25"/>
                    <measurement group_id="O7" value="5.11" spread="10.62"/>
                    <measurement group_id="O8" value="2.48" spread="7.46"/>
                    <measurement group_id="O9" value="1.21" spread="9.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.03" spread="5.98"/>
                    <measurement group_id="O2" value="2.51" spread="7.23"/>
                    <measurement group_id="O3" value="4.17" spread="6.52"/>
                    <measurement group_id="O4" value="1.20" spread="5.88"/>
                    <measurement group_id="O5" value="5.85" spread="7.62"/>
                    <measurement group_id="O6" value="5.85" spread="7.11"/>
                    <measurement group_id="O7" value="4.81" spread="10.33"/>
                    <measurement group_id="O8" value="3.95" spread="6.61"/>
                    <measurement group_id="O9" value="1.39" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental health</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" spread="7.76"/>
                    <measurement group_id="O2" value="0.24" spread="6.57"/>
                    <measurement group_id="O3" value="2.82" spread="8.67"/>
                    <measurement group_id="O4" value="-0.55" spread="6.48"/>
                    <measurement group_id="O5" value="2.47" spread="7.03"/>
                    <measurement group_id="O6" value="1.02" spread="6.93"/>
                    <measurement group_id="O7" value="1.64" spread="6.84"/>
                    <measurement group_id="O8" value="1.91" spread="6.06"/>
                    <measurement group_id="O9" value="-0.38" spread="8.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" spread="6.92"/>
                    <measurement group_id="O2" value="4.67" spread="8.17"/>
                    <measurement group_id="O3" value="6.52" spread="5.91"/>
                    <measurement group_id="O4" value="4.75" spread="4.07"/>
                    <measurement group_id="O5" value="8.74" spread="7.66"/>
                    <measurement group_id="O6" value="7.27" spread="6.32"/>
                    <measurement group_id="O7" value="7.28" spread="6.27"/>
                    <measurement group_id="O8" value="6.79" spread="6.40"/>
                    <measurement group_id="O9" value="2.28" spread="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-emotional</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="6.35"/>
                    <measurement group_id="O2" value="-1.69" spread="6.61"/>
                    <measurement group_id="O3" value="1.17" spread="7.03"/>
                    <measurement group_id="O4" value="1.25" spread="7.47"/>
                    <measurement group_id="O5" value="2.24" spread="8.91"/>
                    <measurement group_id="O6" value="0.18" spread="3.69"/>
                    <measurement group_id="O7" value="2.11" spread="6.17"/>
                    <measurement group_id="O8" value="0.25" spread="5.01"/>
                    <measurement group_id="O9" value="0.63" spread="5.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-physical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.45" spread="8.24"/>
                    <measurement group_id="O2" value="4.37" spread="10.23"/>
                    <measurement group_id="O3" value="7.35" spread="8.85"/>
                    <measurement group_id="O4" value="3.40" spread="5.43"/>
                    <measurement group_id="O5" value="4.53" spread="7.45"/>
                    <measurement group_id="O6" value="7.12" spread="8.21"/>
                    <measurement group_id="O7" value="5.51" spread="8.49"/>
                    <measurement group_id="O8" value="5.37" spread="6.82"/>
                    <measurement group_id="O9" value="1.52" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="6.54"/>
                    <measurement group_id="O2" value="0.71" spread="7.04"/>
                    <measurement group_id="O3" value="1.36" spread="7.69"/>
                    <measurement group_id="O4" value="-0.88" spread="8.81"/>
                    <measurement group_id="O5" value="2.81" spread="9.65"/>
                    <measurement group_id="O6" value="2.23" spread="7.07"/>
                    <measurement group_id="O7" value="-0.91" spread="11.10"/>
                    <measurement group_id="O8" value="0.35" spread="5.62"/>
                    <measurement group_id="O9" value="-0.29" spread="7.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="7.61"/>
                    <measurement group_id="O2" value="5.16" spread="11.08"/>
                    <measurement group_id="O3" value="8.90" spread="8.61"/>
                    <measurement group_id="O4" value="3.22" spread="6.42"/>
                    <measurement group_id="O5" value="9.37" spread="9.75"/>
                    <measurement group_id="O6" value="5.96" spread="7.94"/>
                    <measurement group_id="O7" value="7.02" spread="9.35"/>
                    <measurement group_id="O8" value="4.83" spread="10.84"/>
                    <measurement group_id="O9" value="3.38" spread="10.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical component summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" spread="7.70"/>
                    <measurement group_id="O2" value="5.51" spread="8.04"/>
                    <measurement group_id="O3" value="7.14" spread="6.38"/>
                    <measurement group_id="O4" value="4.70" spread="4.67"/>
                    <measurement group_id="O5" value="7.67" spread="6.93"/>
                    <measurement group_id="O6" value="7.54" spread="8.29"/>
                    <measurement group_id="O7" value="7.28" spread="8.54"/>
                    <measurement group_id="O8" value="6.21" spread="5.68"/>
                    <measurement group_id="O9" value="2.29" spread="9.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental component summary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" spread="5.94"/>
                    <measurement group_id="O2" value="-1.15" spread="6.67"/>
                    <measurement group_id="O3" value="1.45" spread="8.54"/>
                    <measurement group_id="O4" value="-1.10" spread="7.79"/>
                    <measurement group_id="O5" value="1.97" spread="8.26"/>
                    <measurement group_id="O6" value="-0.25" spread="6.66"/>
                    <measurement group_id="O7" value="0.20" spread="7.13"/>
                    <measurement group_id="O8" value="-0.26" spread="5.69"/>
                    <measurement group_id="O9" value="-0.05" spread="6.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Change in Concomitant Medications (Antihypertensive and Lipid-lowering Medications)</title>
        <description>Participants' status on receiving concomitant medication (antihypertensive and lipid-lowering medications) at week 0 (yes/no) and week 52 (decreased, no change, increased or missing) are presented. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, Week 52</time_frame>
        <population>Overall number of participants analyzed = FAS which included all randomised participants. Number Analyzed = number of participants in the FAS with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Change in Concomitant Medications (Antihypertensive and Lipid-lowering Medications)</title>
          <description>Participants' status on receiving concomitant medication (antihypertensive and lipid-lowering medications) at week 0 (yes/no) and week 52 (decreased, no change, increased or missing) are presented. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = FAS which included all randomised participants. Number Analyzed = number of participants in the FAS with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0: Antihypertensive medication (Yes)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="29"/>
                    <measurement group_id="O8" value="36"/>
                    <measurement group_id="O9" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0: Antihypertensive medication (No)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="72"/>
                    <measurement group_id="O5" value="66"/>
                    <measurement group_id="O6" value="70"/>
                    <measurement group_id="O7" value="74"/>
                    <measurement group_id="O8" value="67"/>
                    <measurement group_id="O9" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Antihypertensive medication (Decreased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="7"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Antihypertensive medication (No change)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="76"/>
                    <measurement group_id="O4" value="75"/>
                    <measurement group_id="O5" value="70"/>
                    <measurement group_id="O6" value="64"/>
                    <measurement group_id="O7" value="80"/>
                    <measurement group_id="O8" value="74"/>
                    <measurement group_id="O9" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Antihypertensive medication (Increased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="8"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Antihypertensive medication (Missing)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0: Lipid-lowering medication (Yes)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="13"/>
                    <measurement group_id="O8" value="25"/>
                    <measurement group_id="O9" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0: Lipid-lowering medication (No)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="88"/>
                    <measurement group_id="O5" value="80"/>
                    <measurement group_id="O6" value="82"/>
                    <measurement group_id="O7" value="90"/>
                    <measurement group_id="O8" value="78"/>
                    <measurement group_id="O9" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Lipid-lowering medication (Decreased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                    <measurement group_id="O7" value="3"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Lipid-lowering medication (No change)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="84"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="71"/>
                    <measurement group_id="O7" value="87"/>
                    <measurement group_id="O8" value="83"/>
                    <measurement group_id="O9" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Lipid-lowering medication (Increased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52: Lipid-lowering medication (Missing)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="82"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance With Nutritional Counselling</title>
        <description>This outcome measure presents &quot;nutritional compliance results&quot; recorded at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52. Nutritional compliance was recorded on a 0 to 10 numeric rating scale (NRS), with higher scores representing better compliance.</description>
        <time_frame>Week 4-52</time_frame>
        <population>Overall number of participants analyzed = FAS which included all randomised participants. Number Analyzed = number of participants in the FAS with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Compliance With Nutritional Counselling</title>
          <description>This outcome measure presents &quot;nutritional compliance results&quot; recorded at weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52. Nutritional compliance was recorded on a 0 to 10 numeric rating scale (NRS), with higher scores representing better compliance.</description>
          <population>Overall number of participants analyzed = FAS which included all randomised participants. Number Analyzed = number of participants in the FAS with available data.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week-4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="99"/>
                    <count group_id="O6" value="96"/>
                    <count group_id="O7" value="101"/>
                    <count group_id="O8" value="101"/>
                    <count group_id="O9" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="1.99"/>
                    <measurement group_id="O2" value="7.30" spread="1.96"/>
                    <measurement group_id="O3" value="7.17" spread="1.89"/>
                    <measurement group_id="O4" value="7.07" spread="2.27"/>
                    <measurement group_id="O5" value="7.20" spread="2.19"/>
                    <measurement group_id="O6" value="7.05" spread="2.02"/>
                    <measurement group_id="O7" value="7.30" spread="1.84"/>
                    <measurement group_id="O8" value="7.21" spread="2.13"/>
                    <measurement group_id="O9" value="6.08" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="97"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="96"/>
                    <count group_id="O6" value="89"/>
                    <count group_id="O7" value="99"/>
                    <count group_id="O8" value="97"/>
                    <count group_id="O9" value="124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.53" spread="2.28"/>
                    <measurement group_id="O2" value="7.24" spread="1.91"/>
                    <measurement group_id="O3" value="6.82" spread="2.06"/>
                    <measurement group_id="O4" value="7.13" spread="2.03"/>
                    <measurement group_id="O5" value="7.00" spread="2.16"/>
                    <measurement group_id="O6" value="7.25" spread="1.84"/>
                    <measurement group_id="O7" value="7.65" spread="1.76"/>
                    <measurement group_id="O8" value="6.92" spread="2.18"/>
                    <measurement group_id="O9" value="5.85" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="95"/>
                    <count group_id="O6" value="83"/>
                    <count group_id="O7" value="94"/>
                    <count group_id="O8" value="95"/>
                    <count group_id="O9" value="118"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.70" spread="2.13"/>
                    <measurement group_id="O2" value="7.26" spread="2.26"/>
                    <measurement group_id="O3" value="7.22" spread="2.05"/>
                    <measurement group_id="O4" value="7.04" spread="2.17"/>
                    <measurement group_id="O5" value="7.11" spread="2.26"/>
                    <measurement group_id="O6" value="7.35" spread="1.96"/>
                    <measurement group_id="O7" value="7.64" spread="1.71"/>
                    <measurement group_id="O8" value="7.01" spread="1.93"/>
                    <measurement group_id="O9" value="6.14" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="88"/>
                    <count group_id="O6" value="82"/>
                    <count group_id="O7" value="95"/>
                    <count group_id="O8" value="94"/>
                    <count group_id="O9" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.85" spread="2.08"/>
                    <measurement group_id="O2" value="7.22" spread="1.96"/>
                    <measurement group_id="O3" value="7.36" spread="1.92"/>
                    <measurement group_id="O4" value="7.04" spread="2.05"/>
                    <measurement group_id="O5" value="7.61" spread="1.87"/>
                    <measurement group_id="O6" value="7.27" spread="2.11"/>
                    <measurement group_id="O7" value="7.71" spread="1.66"/>
                    <measurement group_id="O8" value="6.98" spread="1.87"/>
                    <measurement group_id="O9" value="6.31" spread="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="92"/>
                    <count group_id="O5" value="88"/>
                    <count group_id="O6" value="82"/>
                    <count group_id="O7" value="90"/>
                    <count group_id="O8" value="88"/>
                    <count group_id="O9" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" spread="2.01"/>
                    <measurement group_id="O2" value="7.20" spread="1.98"/>
                    <measurement group_id="O3" value="6.87" spread="2.10"/>
                    <measurement group_id="O4" value="7.14" spread="1.88"/>
                    <measurement group_id="O5" value="7.64" spread="1.68"/>
                    <measurement group_id="O6" value="7.24" spread="2.16"/>
                    <measurement group_id="O7" value="7.74" spread="1.47"/>
                    <measurement group_id="O8" value="6.85" spread="2.20"/>
                    <measurement group_id="O9" value="6.24" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="82"/>
                    <count group_id="O7" value="89"/>
                    <count group_id="O8" value="89"/>
                    <count group_id="O9" value="110"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.49" spread="2.25"/>
                    <measurement group_id="O2" value="7.14" spread="2.05"/>
                    <measurement group_id="O3" value="7.07" spread="2.16"/>
                    <measurement group_id="O4" value="7.17" spread="1.86"/>
                    <measurement group_id="O5" value="7.63" spread="1.76"/>
                    <measurement group_id="O6" value="7.05" spread="1.96"/>
                    <measurement group_id="O7" value="7.55" spread="1.86"/>
                    <measurement group_id="O8" value="6.69" spread="2.12"/>
                    <measurement group_id="O9" value="6.06" spread="2.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="84"/>
                    <count group_id="O6" value="80"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="87"/>
                    <count group_id="O9" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" spread="2.04"/>
                    <measurement group_id="O2" value="7.54" spread="1.78"/>
                    <measurement group_id="O3" value="7.10" spread="2.04"/>
                    <measurement group_id="O4" value="7.11" spread="1.73"/>
                    <measurement group_id="O5" value="7.46" spread="1.94"/>
                    <measurement group_id="O6" value="7.53" spread="1.57"/>
                    <measurement group_id="O7" value="7.47" spread="1.90"/>
                    <measurement group_id="O8" value="6.69" spread="2.04"/>
                    <measurement group_id="O9" value="6.34" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="78"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="2.12"/>
                    <measurement group_id="O2" value="6.97" spread="2.23"/>
                    <measurement group_id="O3" value="7.12" spread="1.93"/>
                    <measurement group_id="O4" value="7.07" spread="2.07"/>
                    <measurement group_id="O5" value="7.72" spread="1.76"/>
                    <measurement group_id="O6" value="7.13" spread="2.23"/>
                    <measurement group_id="O7" value="7.29" spread="1.91"/>
                    <measurement group_id="O8" value="6.94" spread="2.01"/>
                    <measurement group_id="O9" value="5.86" spread="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="83"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="88"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" spread="1.94"/>
                    <measurement group_id="O2" value="7.12" spread="2.02"/>
                    <measurement group_id="O3" value="7.03" spread="2.28"/>
                    <measurement group_id="O4" value="6.86" spread="1.98"/>
                    <measurement group_id="O5" value="7.20" spread="2.02"/>
                    <measurement group_id="O6" value="7.33" spread="1.84"/>
                    <measurement group_id="O7" value="7.34" spread="1.57"/>
                    <measurement group_id="O8" value="6.63" spread="2.16"/>
                    <measurement group_id="O9" value="6.10" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="84"/>
                    <count group_id="O6" value="77"/>
                    <count group_id="O7" value="88"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.86" spread="1.96"/>
                    <measurement group_id="O2" value="6.88" spread="2.40"/>
                    <measurement group_id="O3" value="7.07" spread="2.05"/>
                    <measurement group_id="O4" value="7.03" spread="1.97"/>
                    <measurement group_id="O5" value="7.40" spread="1.89"/>
                    <measurement group_id="O6" value="7.01" spread="1.81"/>
                    <measurement group_id="O7" value="7.26" spread="1.87"/>
                    <measurement group_id="O8" value="6.52" spread="2.07"/>
                    <measurement group_id="O9" value="5.90" spread="2.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="84"/>
                    <count group_id="O5" value="80"/>
                    <count group_id="O6" value="78"/>
                    <count group_id="O7" value="88"/>
                    <count group_id="O8" value="80"/>
                    <count group_id="O9" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.83" spread="1.82"/>
                    <measurement group_id="O2" value="6.95" spread="2.10"/>
                    <measurement group_id="O3" value="6.96" spread="1.92"/>
                    <measurement group_id="O4" value="6.96" spread="2.01"/>
                    <measurement group_id="O5" value="7.30" spread="2.13"/>
                    <measurement group_id="O6" value="6.87" spread="1.98"/>
                    <measurement group_id="O7" value="7.30" spread="1.98"/>
                    <measurement group_id="O8" value="6.60" spread="1.85"/>
                    <measurement group_id="O9" value="5.99" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="84"/>
                    <count group_id="O5" value="81"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="87"/>
                    <count group_id="O8" value="82"/>
                    <count group_id="O9" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.82" spread="2.08"/>
                    <measurement group_id="O2" value="7.05" spread="1.91"/>
                    <measurement group_id="O3" value="6.88" spread="2.00"/>
                    <measurement group_id="O4" value="6.92" spread="2.16"/>
                    <measurement group_id="O5" value="7.12" spread="2.31"/>
                    <measurement group_id="O6" value="7.01" spread="2.03"/>
                    <measurement group_id="O7" value="7.23" spread="1.78"/>
                    <measurement group_id="O8" value="6.01" spread="2.49"/>
                    <measurement group_id="O9" value="6.16" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week-52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="74"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="81"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="89"/>
                    <count group_id="O8" value="85"/>
                    <count group_id="O9" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.23" spread="1.69"/>
                    <measurement group_id="O2" value="7.22" spread="1.98"/>
                    <measurement group_id="O3" value="7.05" spread="2.04"/>
                    <measurement group_id="O4" value="6.85" spread="2.47"/>
                    <measurement group_id="O5" value="7.36" spread="2.22"/>
                    <measurement group_id="O6" value="7.36" spread="1.85"/>
                    <measurement group_id="O7" value="7.31" spread="2.02"/>
                    <measurement group_id="O8" value="6.87" spread="2.07"/>
                    <measurement group_id="O9" value="6.09" spread="2.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of AEs During the Trial</title>
        <description>Adverse events (AEs) were recorded from week 0 to week 59. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0-59</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of AEs During the Trial</title>
          <description>Adverse events (AEs) were recorded from week 0 to week 59. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547"/>
                    <measurement group_id="O2" value="730"/>
                    <measurement group_id="O3" value="738"/>
                    <measurement group_id="O4" value="587"/>
                    <measurement group_id="O5" value="775"/>
                    <measurement group_id="O6" value="737"/>
                    <measurement group_id="O7" value="681"/>
                    <measurement group_id="O8" value="612"/>
                    <measurement group_id="O9" value="650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hypoglycaemic Episodes During the Trial</title>
        <description>Hypoglycaemic episodes were identified by either: 1) Subject reporting of symptoms of hypoglycaemia (low blood sugar) or 2) fasting plasma glucose (FPG) values ≤3.9 mmol/L (70 mg/dL) from blood sampling at site visits. Hypoglycaemic episodes were recorded from week 0 to week 59. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0-59</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hypoglycaemic Episodes During the Trial</title>
          <description>Hypoglycaemic episodes were identified by either: 1) Subject reporting of symptoms of hypoglycaemia (low blood sugar) or 2) fasting plasma glucose (FPG) values ≤3.9 mmol/L (70 mg/dL) from blood sampling at site visits. Hypoglycaemic episodes were recorded from week 0 to week 59. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="20"/>
                    <measurement group_id="O7" value="16"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New and Ongoing Nausea, Vomiting, Diarrhoea, and Constipation Events by Week</title>
        <description>Presented results are the number of nausea, vomiting, diarrhoea, and constipation events recorded from week 0 to week 59. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 0-59</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New and Ongoing Nausea, Vomiting, Diarrhoea, and Constipation Events by Week</title>
          <description>Presented results are the number of nausea, vomiting, diarrhoea, and constipation events recorded from week 0 to week 59. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="69"/>
                    <measurement group_id="O5" value="94"/>
                    <measurement group_id="O6" value="106"/>
                    <measurement group_id="O7" value="97"/>
                    <measurement group_id="O8" value="89"/>
                    <measurement group_id="O9" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="47"/>
                    <measurement group_id="O8" value="17"/>
                    <measurement group_id="O9" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="63"/>
                    <measurement group_id="O6" value="54"/>
                    <measurement group_id="O7" value="49"/>
                    <measurement group_id="O8" value="46"/>
                    <measurement group_id="O9" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Constipation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="25"/>
                    <measurement group_id="O5" value="35"/>
                    <measurement group_id="O6" value="23"/>
                    <measurement group_id="O7" value="34"/>
                    <measurement group_id="O8" value="30"/>
                    <measurement group_id="O9" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nausea: Individual Scores of Nausea Questionnaire and Severity by NRS Score</title>
        <description>This outcome measure presents results recorded at week 52. If a participant experienced an event of nausea within 24 hours prior to a site visit, a nausea questionnaire had to be completed. Participants experiencing such events were to answer 5 different categories in the questionnaire ('duration of nausea', 'time from the latest injection of trial product to the onset of nausea', 'time from last food intake to the onset of nausea', 'nausea accompanied by vomiting (yes/no)' and 'severity of nausea (worst during episode)'). Severity of nausea was recorded on a 0 to 10 numeric rating scale (NRS), where 0 = 'No nausea' and 10 = 'Nausea as bad as it could be'. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
        <time_frame>Week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the SAS who experienced an event of nausea within 24 hours prior to the site visit at week 52. SAS included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Nausea: Individual Scores of Nausea Questionnaire and Severity by NRS Score</title>
          <description>This outcome measure presents results recorded at week 52. If a participant experienced an event of nausea within 24 hours prior to a site visit, a nausea questionnaire had to be completed. Participants experiencing such events were to answer 5 different categories in the questionnaire ('duration of nausea', 'time from the latest injection of trial product to the onset of nausea', 'time from last food intake to the onset of nausea', 'nausea accompanied by vomiting (yes/no)' and 'severity of nausea (worst during episode)'). Severity of nausea was recorded on a 0 to 10 numeric rating scale (NRS), where 0 = 'No nausea' and 10 = 'Nausea as bad as it could be'. Results are based on the in-trial observation period which was defined as the period from randomisation to last contact with trial site.</description>
          <population>Overall number of participants analyzed = number of participants in the SAS who experienced an event of nausea within 24 hours prior to the site visit at week 52. SAS included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Nausea events</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Nausea events</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Duration of nausea:&lt;30 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of nausea: 30 min-2 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of nausea: 2-4 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of nausea: 4-8 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of nausea: &gt;8 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latest injection to onset time: 0-3 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latest injection to onset time: 3-6 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latest injection to onset time: 6-12 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latest injection to onset time: 12-18 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latest injection to onset time: &gt;18 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last food intake to onset time: 0-1 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last food intake to onset time: 1-2 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last food intake to onset time: 2-3 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last food intake to onset time: 3-6 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last food intake to onset time: &gt;6 hr</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea accompanied by vomiting (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea accompanied by vomiting (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severity of nausea: 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in ECG</title>
        <description>Number of participants with electrocardiogram (ECG) results, &quot;normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)&quot; was recorded at baseline (week 0) and week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in ECG</title>
          <description>Number of participants with electrocardiogram (ECG) results, &quot;normal; abnormal, not clinically significant (NCS) or abnormal, clinically significant (CS)&quot; was recorded at baseline (week 0) and week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week: 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="62"/>
                    <measurement group_id="O6" value="70"/>
                    <measurement group_id="O7" value="74"/>
                    <measurement group_id="O8" value="68"/>
                    <measurement group_id="O9" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="41"/>
                    <measurement group_id="O5" value="38"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="27"/>
                    <measurement group_id="O8" value="35"/>
                    <measurement group_id="O9" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week: 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="82"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="89"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="77"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Normal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="57"/>
                    <measurement group_id="O6" value="55"/>
                    <measurement group_id="O7" value="64"/>
                    <measurement group_id="O8" value="59"/>
                    <measurement group_id="O9" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, NCS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="31"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="21"/>
                    <measurement group_id="O7" value="28"/>
                    <measurement group_id="O8" value="26"/>
                    <measurement group_id="O9" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Abnormal, CS</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pulse</title>
        <description>Change from baseline (week 0) in pulse rate was evaluated at week 52. Analysis of observed data using a mixed model for repeated measurements (MMRM) with treatment, region and sex as factors and baseline pulse as covariate, all nested within visit. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pulse</title>
          <description>Change from baseline (week 0) in pulse rate was evaluated at week 52. Analysis of observed data using a mixed model for repeated measurements (MMRM) with treatment, region and sex as factors and baseline pulse as covariate, all nested within visit. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.88"/>
                    <measurement group_id="O2" value="3.46" spread="0.83"/>
                    <measurement group_id="O3" value="1.88" spread="0.84"/>
                    <measurement group_id="O4" value="2.38" spread="0.83"/>
                    <measurement group_id="O5" value="2.54" spread="0.85"/>
                    <measurement group_id="O6" value="2.34" spread="0.89"/>
                    <measurement group_id="O7" value="2.15" spread="0.82"/>
                    <measurement group_id="O8" value="2.63" spread="0.84"/>
                    <measurement group_id="O9" value="-0.86" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Haematology: Haemoglobin</title>
        <description>Change from baseline (week 0) in haemoglobin was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haematology: Haemoglobin</title>
          <description>Change from baseline (week 0) in haemoglobin was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Millimoles per litre (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="85"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="91"/>
                <count group_id="O8" value="84"/>
                <count group_id="O9" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.48"/>
                    <measurement group_id="O2" value="-0.08" spread="0.65"/>
                    <measurement group_id="O3" value="-0.02" spread="0.47"/>
                    <measurement group_id="O4" value="-0.07" spread="0.51"/>
                    <measurement group_id="O5" value="0.00" spread="0.50"/>
                    <measurement group_id="O6" value="-0.07" spread="0.47"/>
                    <measurement group_id="O7" value="0.02" spread="0.47"/>
                    <measurement group_id="O8" value="0.11" spread="0.48"/>
                    <measurement group_id="O9" value="-0.01" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Haematology: Haematocrit</title>
        <description>Change from baseline (week 0) in haematocrit was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haematology: Haematocrit</title>
          <description>Change from baseline (week 0) in haematocrit was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Percentage of red blood cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="85"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="91"/>
                <count group_id="O8" value="84"/>
                <count group_id="O9" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="2.48"/>
                    <measurement group_id="O2" value="-0.58" spread="3.28"/>
                    <measurement group_id="O3" value="-0.42" spread="2.26"/>
                    <measurement group_id="O4" value="-0.49" spread="2.67"/>
                    <measurement group_id="O5" value="-0.31" spread="2.75"/>
                    <measurement group_id="O6" value="-0.68" spread="2.82"/>
                    <measurement group_id="O7" value="-0.15" spread="2.67"/>
                    <measurement group_id="O8" value="0.26" spread="2.70"/>
                    <measurement group_id="O9" value="0.26" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Haematology: Thrombocytes, Leucocytes and Differential Count</title>
        <description>Change from baseline (week 0) in haematological parameters, &quot;thrombocytes, leucocytes and differential cell count (eosinophils, neutrophils, basophils, monocytes and lymphocytes)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haematology: Thrombocytes, Leucocytes and Differential Count</title>
          <description>Change from baseline (week 0) in haematological parameters, &quot;thrombocytes, leucocytes and differential cell count (eosinophils, neutrophils, basophils, monocytes and lymphocytes)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
          <units>10^9 cells/litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Thrombocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="35.26"/>
                    <measurement group_id="O2" value="2.95" spread="43.02"/>
                    <measurement group_id="O3" value="-8.17" spread="42.59"/>
                    <measurement group_id="O4" value="2.79" spread="41.28"/>
                    <measurement group_id="O5" value="-0.52" spread="39.59"/>
                    <measurement group_id="O6" value="-5.76" spread="53.41"/>
                    <measurement group_id="O7" value="-3.32" spread="45.02"/>
                    <measurement group_id="O8" value="4.83" spread="37.70"/>
                    <measurement group_id="O9" value="-6.11" spread="39.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leucocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="1.38"/>
                    <measurement group_id="O2" value="-0.24" spread="1.44"/>
                    <measurement group_id="O3" value="-0.23" spread="1.81"/>
                    <measurement group_id="O4" value="-0.50" spread="1.42"/>
                    <measurement group_id="O5" value="-0.68" spread="1.41"/>
                    <measurement group_id="O6" value="-0.66" spread="1.90"/>
                    <measurement group_id="O7" value="-0.40" spread="1.43"/>
                    <measurement group_id="O8" value="-0.17" spread="1.41"/>
                    <measurement group_id="O9" value="-0.44" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="73"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.11"/>
                    <measurement group_id="O2" value="0.02" spread="0.16"/>
                    <measurement group_id="O3" value="-0.01" spread="0.09"/>
                    <measurement group_id="O4" value="-0.02" spread="0.13"/>
                    <measurement group_id="O5" value="0.00" spread="0.08"/>
                    <measurement group_id="O6" value="0.01" spread="0.09"/>
                    <measurement group_id="O7" value="-0.01" spread="0.08"/>
                    <measurement group_id="O8" value="0.01" spread="0.10"/>
                    <measurement group_id="O9" value="0.00" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="73"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="1.17"/>
                    <measurement group_id="O2" value="-0.07" spread="1.22"/>
                    <measurement group_id="O3" value="-0.05" spread="1.62"/>
                    <measurement group_id="O4" value="-0.22" spread="1.24"/>
                    <measurement group_id="O5" value="-0.51" spread="1.27"/>
                    <measurement group_id="O6" value="-0.57" spread="1.76"/>
                    <measurement group_id="O7" value="-0.23" spread="1.19"/>
                    <measurement group_id="O8" value="-0.12" spread="1.11"/>
                    <measurement group_id="O9" value="-0.33" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="73"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.03"/>
                    <measurement group_id="O2" value="-0.00" spread="0.04"/>
                    <measurement group_id="O3" value="-0.00" spread="0.03"/>
                    <measurement group_id="O4" value="-0.01" spread="0.03"/>
                    <measurement group_id="O5" value="-0.00" spread="0.03"/>
                    <measurement group_id="O6" value="-0.01" spread="0.04"/>
                    <measurement group_id="O7" value="0.00" spread="0.04"/>
                    <measurement group_id="O8" value="-0.00" spread="0.04"/>
                    <measurement group_id="O9" value="0.00" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="73"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.18"/>
                    <measurement group_id="O2" value="-0.04" spread="0.12"/>
                    <measurement group_id="O3" value="0.01" spread="0.12"/>
                    <measurement group_id="O4" value="-0.02" spread="0.10"/>
                    <measurement group_id="O5" value="-0.02" spread="0.12"/>
                    <measurement group_id="O6" value="-0.01" spread="0.13"/>
                    <measurement group_id="O7" value="-0.03" spread="0.11"/>
                    <measurement group_id="O8" value="-0.01" spread="0.14"/>
                    <measurement group_id="O9" value="-0.02" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="86"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="73"/>
                    <count group_id="O7" value="91"/>
                    <count group_id="O8" value="84"/>
                    <count group_id="O9" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.36"/>
                    <measurement group_id="O2" value="-0.16" spread="0.46"/>
                    <measurement group_id="O3" value="-0.17" spread="0.38"/>
                    <measurement group_id="O4" value="-0.24" spread="0.50"/>
                    <measurement group_id="O5" value="-0.15" spread="0.36"/>
                    <measurement group_id="O6" value="-0.08" spread="0.41"/>
                    <measurement group_id="O7" value="-0.14" spread="0.37"/>
                    <measurement group_id="O8" value="-0.06" spread="0.42"/>
                    <measurement group_id="O9" value="-0.09" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Haematology: Erythrocytes</title>
        <description>Change from baseline (week 0) in erythrocytes was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Haematology: Erythrocytes</title>
          <description>Change from baseline (week 0) in erythrocytes was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
          <units>10^12 cells/litre (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="86"/>
                <count group_id="O5" value="85"/>
                <count group_id="O6" value="75"/>
                <count group_id="O7" value="91"/>
                <count group_id="O8" value="84"/>
                <count group_id="O9" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.26"/>
                    <measurement group_id="O2" value="-0.06" spread="0.35"/>
                    <measurement group_id="O3" value="-0.03" spread="0.27"/>
                    <measurement group_id="O4" value="-0.04" spread="0.25"/>
                    <measurement group_id="O5" value="-0.01" spread="0.29"/>
                    <measurement group_id="O6" value="-0.04" spread="0.24"/>
                    <measurement group_id="O7" value="-0.01" spread="0.27"/>
                    <measurement group_id="O8" value="0.05" spread="0.30"/>
                    <measurement group_id="O9" value="0.04" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biochemistry: Creatinine and Bilirubin (Total)</title>
        <description>Change from baseline (week 0) in biochemistry parameters, &quot;creatinine and bilirubin (total)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biochemistry: Creatinine and Bilirubin (Total)</title>
          <description>Change from baseline (week 0) in biochemistry parameters, &quot;creatinine and bilirubin (total)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
          <units>Micromole/litre (umol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.14" spread="6.53"/>
                    <measurement group_id="O2" value="-0.85" spread="7.59"/>
                    <measurement group_id="O3" value="-1.09" spread="6.11"/>
                    <measurement group_id="O4" value="0.76" spread="8.11"/>
                    <measurement group_id="O5" value="1.48" spread="29.73"/>
                    <measurement group_id="O6" value="1.05" spread="8.45"/>
                    <measurement group_id="O7" value="-2.10" spread="8.49"/>
                    <measurement group_id="O8" value="-0.81" spread="7.16"/>
                    <measurement group_id="O9" value="0.28" spread="8.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin (total)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="85"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="3.70"/>
                    <measurement group_id="O2" value="1.12" spread="3.60"/>
                    <measurement group_id="O3" value="1.59" spread="3.11"/>
                    <measurement group_id="O4" value="1.33" spread="3.61"/>
                    <measurement group_id="O5" value="1.23" spread="5.18"/>
                    <measurement group_id="O6" value="1.02" spread="4.04"/>
                    <measurement group_id="O7" value="1.67" spread="4.28"/>
                    <measurement group_id="O8" value="1.02" spread="3.67"/>
                    <measurement group_id="O9" value="1.09" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biochemistry: Creatinine Kinase, Amylase, Lipase, ALT, AST and ALP</title>
        <description>Change from baseline (week 0) in biochemistry parameters, &quot;creatinine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biochemistry: Creatinine Kinase, Amylase, Lipase, ALT, AST and ALP</title>
          <description>Change from baseline (week 0) in biochemistry parameters, &quot;creatinine kinase, amylase, lipase, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
          <units>Unit/litre (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine kinase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.53" spread="68.43"/>
                    <measurement group_id="O2" value="-44.75" spread="266.88"/>
                    <measurement group_id="O3" value="-13.20" spread="44.33"/>
                    <measurement group_id="O4" value="-46.34" spread="163.09"/>
                    <measurement group_id="O5" value="-29.91" spread="95.05"/>
                    <measurement group_id="O6" value="-8.86" spread="47.28"/>
                    <measurement group_id="O7" value="-28.08" spread="122.61"/>
                    <measurement group_id="O8" value="-3.09" spread="172.46"/>
                    <measurement group_id="O9" value="53.36" spread="571.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="13.82"/>
                    <measurement group_id="O2" value="4.84" spread="13.05"/>
                    <measurement group_id="O3" value="9.20" spread="12.72"/>
                    <measurement group_id="O4" value="7.53" spread="13.94"/>
                    <measurement group_id="O5" value="7.67" spread="16.26"/>
                    <measurement group_id="O6" value="8.39" spread="20.28"/>
                    <measurement group_id="O7" value="7.78" spread="14.82"/>
                    <measurement group_id="O8" value="7.12" spread="15.72"/>
                    <measurement group_id="O9" value="3.41" spread="12.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.62" spread="32.22"/>
                    <measurement group_id="O2" value="8.83" spread="28.10"/>
                    <measurement group_id="O3" value="17.55" spread="41.20"/>
                    <measurement group_id="O4" value="13.28" spread="34.86"/>
                    <measurement group_id="O5" value="13.33" spread="17.92"/>
                    <measurement group_id="O6" value="14.92" spread="44.31"/>
                    <measurement group_id="O7" value="15.09" spread="36.28"/>
                    <measurement group_id="O8" value="11.86" spread="27.48"/>
                    <measurement group_id="O9" value="1.63" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="85"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.82" spread="20.97"/>
                    <measurement group_id="O2" value="-5.45" spread="12.64"/>
                    <measurement group_id="O3" value="-7.44" spread="17.14"/>
                    <measurement group_id="O4" value="-9.15" spread="23.09"/>
                    <measurement group_id="O5" value="-3.64" spread="11.30"/>
                    <measurement group_id="O6" value="-9.07" spread="20.96"/>
                    <measurement group_id="O7" value="-7.17" spread="12.62"/>
                    <measurement group_id="O8" value="-2.95" spread="14.19"/>
                    <measurement group_id="O9" value="-3.03" spread="11.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="83"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="12.17"/>
                    <measurement group_id="O2" value="-1.99" spread="7.95"/>
                    <measurement group_id="O3" value="-2.33" spread="7.61"/>
                    <measurement group_id="O4" value="-3.32" spread="10.22"/>
                    <measurement group_id="O5" value="-2.07" spread="6.70"/>
                    <measurement group_id="O6" value="-1.62" spread="10.78"/>
                    <measurement group_id="O7" value="-2.73" spread="6.10"/>
                    <measurement group_id="O8" value="-1.48" spread="10.13"/>
                    <measurement group_id="O9" value="0.00" spread="11.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.42" spread="13.04"/>
                    <measurement group_id="O2" value="-3.44" spread="16.00"/>
                    <measurement group_id="O3" value="-6.21" spread="10.96"/>
                    <measurement group_id="O4" value="-6.70" spread="13.89"/>
                    <measurement group_id="O5" value="-4.25" spread="12.65"/>
                    <measurement group_id="O6" value="-3.50" spread="15.61"/>
                    <measurement group_id="O7" value="-8.20" spread="14.13"/>
                    <measurement group_id="O8" value="-0.52" spread="9.80"/>
                    <measurement group_id="O9" value="-1.46" spread="11.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biochemistry: Urea, Sodium, Potassium and Calcium (Total)</title>
        <description>Change from baseline (week 0) in biochemistry parameters, &quot;urea, sodium, potassium and calcium (total)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biochemistry: Urea, Sodium, Potassium and Calcium (Total)</title>
          <description>Change from baseline (week 0) in biochemistry parameters, &quot;urea, sodium, potassium and calcium (total)&quot; were evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
          <units>Millimole/litre (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Urea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="1.06"/>
                    <measurement group_id="O2" value="0.16" spread="1.26"/>
                    <measurement group_id="O3" value="-0.01" spread="1.21"/>
                    <measurement group_id="O4" value="-0.10" spread="1.25"/>
                    <measurement group_id="O5" value="-0.00" spread="1.88"/>
                    <measurement group_id="O6" value="-0.06" spread="1.33"/>
                    <measurement group_id="O7" value="-0.33" spread="1.12"/>
                    <measurement group_id="O8" value="0.03" spread="1.06"/>
                    <measurement group_id="O9" value="0.21" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" spread="2.47"/>
                    <measurement group_id="O2" value="-0.27" spread="1.77"/>
                    <measurement group_id="O3" value="-0.40" spread="2.41"/>
                    <measurement group_id="O4" value="-0.82" spread="2.36"/>
                    <measurement group_id="O5" value="-0.92" spread="2.62"/>
                    <measurement group_id="O6" value="-0.76" spread="3.49"/>
                    <measurement group_id="O7" value="-0.74" spread="2.71"/>
                    <measurement group_id="O8" value="-0.37" spread="2.08"/>
                    <measurement group_id="O9" value="-0.35" spread="2.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="78"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.30"/>
                    <measurement group_id="O2" value="0.01" spread="0.38"/>
                    <measurement group_id="O3" value="-0.00" spread="0.31"/>
                    <measurement group_id="O4" value="-0.04" spread="0.36"/>
                    <measurement group_id="O5" value="-0.10" spread="0.41"/>
                    <measurement group_id="O6" value="0.00" spread="0.36"/>
                    <measurement group_id="O7" value="-0.11" spread="0.44"/>
                    <measurement group_id="O8" value="-0.02" spread="0.35"/>
                    <measurement group_id="O9" value="-0.04" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (total)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="79"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="88"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="76"/>
                    <count group_id="O7" value="92"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.07"/>
                    <measurement group_id="O2" value="-0.01" spread="0.09"/>
                    <measurement group_id="O3" value="0.01" spread="0.08"/>
                    <measurement group_id="O4" value="0.01" spread="0.08"/>
                    <measurement group_id="O5" value="0.00" spread="0.09"/>
                    <measurement group_id="O6" value="-0.00" spread="0.08"/>
                    <measurement group_id="O7" value="0.00" spread="0.09"/>
                    <measurement group_id="O8" value="0.02" spread="0.08"/>
                    <measurement group_id="O9" value="-0.00" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biochemistry: Albumin</title>
        <description>Change from baseline (week 0) in albumin was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biochemistry: Albumin</title>
          <description>Change from baseline (week 0) in albumin was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Gram/decilitre (g/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="85"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="92"/>
                <count group_id="O8" value="86"/>
                <count group_id="O9" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.18"/>
                    <measurement group_id="O2" value="0.01" spread="0.21"/>
                    <measurement group_id="O3" value="0.07" spread="0.20"/>
                    <measurement group_id="O4" value="0.05" spread="0.21"/>
                    <measurement group_id="O5" value="0.03" spread="0.22"/>
                    <measurement group_id="O6" value="0.01" spread="0.21"/>
                    <measurement group_id="O7" value="0.02" spread="0.23"/>
                    <measurement group_id="O8" value="0.06" spread="0.18"/>
                    <measurement group_id="O9" value="0.04" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biochemistry: Calcitonin</title>
        <description>Change from baseline (week 0) in calcitonin was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = number of female participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biochemistry: Calcitonin</title>
          <description>Change from baseline (week 0) in calcitonin was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = number of female participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Nanogram/litre (ng/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="56"/>
                <count group_id="O5" value="58"/>
                <count group_id="O6" value="47"/>
                <count group_id="O7" value="59"/>
                <count group_id="O8" value="57"/>
                <count group_id="O9" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.71"/>
                    <measurement group_id="O2" value="0.03" spread="1.07"/>
                    <measurement group_id="O3" value="0.04" spread="0.44"/>
                    <measurement group_id="O4" value="0.04" spread="0.18"/>
                    <measurement group_id="O5" value="0.17" spread="0.79"/>
                    <measurement group_id="O6" value="-0.01" spread="0.73"/>
                    <measurement group_id="O7" value="0.20" spread="0.72"/>
                    <measurement group_id="O8" value="0.29" spread="1.27"/>
                    <measurement group_id="O9" value="-0.12" spread="2.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Biochemistry: TSH</title>
        <description>Change from baseline (week 0) in thyroid stimulating hormone (TSH) was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Biochemistry: TSH</title>
          <description>Change from baseline (week 0) in thyroid stimulating hormone (TSH) was evaluated at week 52. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = number of participants in the SAS with available data. SAS included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Milli-international units/litre (mIU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="85"/>
                <count group_id="O6" value="76"/>
                <count group_id="O7" value="92"/>
                <count group_id="O8" value="86"/>
                <count group_id="O9" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.31" spread="1.62"/>
                    <measurement group_id="O2" value="-0.10" spread="1.10"/>
                    <measurement group_id="O3" value="-0.22" spread="0.85"/>
                    <measurement group_id="O4" value="-0.18" spread="1.04"/>
                    <measurement group_id="O5" value="-0.10" spread="0.96"/>
                    <measurement group_id="O6" value="-0.12" spread="0.84"/>
                    <measurement group_id="O7" value="-0.43" spread="1.01"/>
                    <measurement group_id="O8" value="0.02" spread="0.88"/>
                    <measurement group_id="O9" value="-0.07" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mental Health Assessed by C-SSRS</title>
        <description>Presented results are the number of participants with Columbia Suicidality Severity Rating Scale (C-SSRS) results recorded during baseline (week 0) and post baseline (week 4-52) visits. For classification of the events reported on the C-SSRS, the following categories were used: 1) Suicidal ideation, 2) Suicidal behaviour and 3) Non-suicidal self-injurious behaviour. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0 and Week 4-59</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mental Health Assessed by C-SSRS</title>
          <description>Presented results are the number of participants with Columbia Suicidality Severity Rating Scale (C-SSRS) results recorded during baseline (week 0) and post baseline (week 4-52) visits. For classification of the events reported on the C-SSRS, the following categories were used: 1) Suicidal ideation, 2) Suicidal behaviour and 3) Non-suicidal self-injurious behaviour. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wk 0: Suicidal ideation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 0: Suicidal behaviour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 0: Non-suicidal self-injurious behaviour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4-59: Suicidal ideation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="102"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="2"/>
                    <measurement group_id="O9" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4-59: Suicidal behaviour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="102"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wk 4-59: Non-suicidal self-injurious behaviour</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="100"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="102"/>
                    <count group_id="O4" value="102"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mental Health Assessed by PHQ-9</title>
        <description>Patient health questionnaire-9 (PHQ-9) was recorded at baseline (week 0) and week 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. On the PHQ-9, the participant rates the frequency of 9 items on a scale from 0 (not at all) to 3 (nearly every day). The PHQ-9 total score ranges from 0−27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15−19 represent moderately severe depression and total scores of 20-27 represent severe depression. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
        <time_frame>Week 0, week 52</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O8">
            <title>Liraglutide 3.0 mg</title>
            <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
          </group>
          <group group_id="O9">
            <title>Placebo Pool</title>
            <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mental Health Assessed by PHQ-9</title>
          <description>Patient health questionnaire-9 (PHQ-9) was recorded at baseline (week 0) and week 52. The PHQ-9 questionnaire is a 9-item depression module included in the patient health questionnaire, a self-administered diagnostic tool used for assessment of mental disorders. On the PHQ-9, the participant rates the frequency of 9 items on a scale from 0 (not at all) to 3 (nearly every day). The PHQ-9 total score ranges from 0−27; total scores of 1-4 represent no depression, total scores of 5-9 represent mild depression, total scores of 10-14 represent moderate depression, total scores of 15−19 represent moderately severe depression and total scores of 20-27 represent severe depression. Results are based on the on-treatment observation period which was defined as the period from first trial product administration to last trial product administration.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment. Number Analyzed = number of participants in the SAS with available data.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
                <count group_id="O8" value="103"/>
                <count group_id="O9" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                    <count group_id="O6" value="102"/>
                    <count group_id="O7" value="103"/>
                    <count group_id="O8" value="103"/>
                    <count group_id="O9" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="3.4"/>
                    <measurement group_id="O2" value="1.7" spread="2.1"/>
                    <measurement group_id="O3" value="2.1" spread="2.6"/>
                    <measurement group_id="O4" value="1.5" spread="1.9"/>
                    <measurement group_id="O5" value="2.5" spread="2.9"/>
                    <measurement group_id="O6" value="1.7" spread="2.6"/>
                    <measurement group_id="O7" value="2.0" spread="2.2"/>
                    <measurement group_id="O8" value="2.0" spread="2.5"/>
                    <measurement group_id="O9" value="2.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="77"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="87"/>
                    <count group_id="O5" value="81"/>
                    <count group_id="O6" value="75"/>
                    <count group_id="O7" value="90"/>
                    <count group_id="O8" value="86"/>
                    <count group_id="O9" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.2"/>
                    <measurement group_id="O2" value="1.1" spread="1.8"/>
                    <measurement group_id="O3" value="1.3" spread="2.0"/>
                    <measurement group_id="O4" value="1.1" spread="1.7"/>
                    <measurement group_id="O5" value="1.0" spread="1.8"/>
                    <measurement group_id="O6" value="1.1" spread="1.4"/>
                    <measurement group_id="O7" value="0.9" spread="1.6"/>
                    <measurement group_id="O8" value="1.3" spread="2.0"/>
                    <measurement group_id="O9" value="1.7" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anti-semaglutide Antibodies During and After Treatment</title>
        <description>Participants were tested for anti-semaglutide antibodies from week 0 (post treatment) to week 52 (at weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52). This outcome measure is applicable only for the semaglutide treatment arms.</description>
        <time_frame>Week 0-52</time_frame>
        <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Semaglutide 0.05 mg</title>
            <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Semaglutide 0.1 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
          </group>
          <group group_id="O3">
            <title>Semaglutide 0.2 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
          </group>
          <group group_id="O4">
            <title>Semaglutide 0.3 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
          </group>
          <group group_id="O5">
            <title>Semaglutide 0.4 mg</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
          </group>
          <group group_id="O6">
            <title>Semaglutide 0.3 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
          </group>
          <group group_id="O7">
            <title>Semaglutide 0.4 mg (Fast Escalation)</title>
            <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
          </group>
        </group_list>
        <measure>
          <title>Anti-semaglutide Antibodies During and After Treatment</title>
          <description>Participants were tested for anti-semaglutide antibodies from week 0 (post treatment) to week 52 (at weeks 0, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52). This outcome measure is applicable only for the semaglutide treatment arms.</description>
          <population>Overall number of participants analyzed = SAS which included all participants receiving at least one dose of the randomised treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="103"/>
                <count group_id="O4" value="103"/>
                <count group_id="O5" value="102"/>
                <count group_id="O6" value="102"/>
                <count group_id="O7" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Week 0 up to Week 59 (treatment period: week 0 to week 52 + follow-up period: week 53 to week 59).</time_frame>
      <desc>All AEs mentioned here are treatment-emergent adverse events (TEAEs), which was defined as any AE reported after first trial product administration and until last trial product administration with a 7-week follow-up period. Results are based on the safety analysis set, which included all subjects receiving at least 1 dose of randomised treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Semaglutide 0.05 mg</title>
          <description>Participants received once daily semaglutide 0.05 mg s.c. injections for 52 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Semaglutide 0.1 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4) and 0.1 mg (week 5 to week 52).</description>
        </group>
        <group group_id="E3">
          <title>Semaglutide 0.2 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), and 0.2 mg (week 9 to week 52).</description>
        </group>
        <group group_id="E4">
          <title>Semaglutide 0.3 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), and 0.3 mg (week 13 to week 52).</description>
        </group>
        <group group_id="E5">
          <title>Semaglutide 0.4 mg</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every fourth week as following: 0.05 mg (week 1 to week 4), 0.1 mg (week 5 to week 8), 0.2 mg (week 9 to week 12), 0.3 mg (week 13 to week 16), and 0.4 mg (week 17 to week 52).</description>
        </group>
        <group group_id="E6">
          <title>Semaglutide 0.3 mg (Fast Escalation)</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), and 0.3 mg (week 7 to week 52).</description>
        </group>
        <group group_id="E7">
          <title>Semaglutide 0.4 mg (Fast Escalation)</title>
          <description>Participants received once daily semaglutide s.c. injections for 52 weeks. Dose escalation was done at every second week (fast escalation) as following: 0.05 mg (in weeks 1 and 2), 0.1 mg (in weeks 3 and 4), 0.2 mg (in weeks 5 and 6), 0.3 mg (in weeks 7 and 8), and 0.4 mg (week 9 to week 52).</description>
        </group>
        <group group_id="E8">
          <title>Liraglutide 3.0 mg</title>
          <description>Participants received once daily liraglutide s.c. injections for 52 weeks. Dose escalation was done at every week as following: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3.0 mg from week 5 to week 52.</description>
        </group>
        <group group_id="E9">
          <title>Placebo Pool</title>
          <description>Participants received once daily placebo s.c injections (matching each of the active treatment arms: semaglutide 0.05 mg, 0.1 mg, 0.2 mg, 0.3 mg or 0.4 mg (dose escalation every fourth week); semaglutide 0.3 mg or 0.4 mg (dose escalation every second week); liraglutide 3.0 mg (dose escalation every week)).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="102"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Very long-chain acyl-coenzyme A dehydrogenase deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Intestinal scarring</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pancreatic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Escherichia coli</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomotic leak</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Human chorionic gonadotropin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Muscle enzyme increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Transitional cell cancer of the renal pelvis and ureter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma-chronic obstructive pulmonary disease overlap syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Livedo reticularis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vascular insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="83" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="103"/>
                <counts group_id="E4" subjects_affected="85" subjects_at_risk="103"/>
                <counts group_id="E5" subjects_affected="90" subjects_at_risk="102"/>
                <counts group_id="E6" subjects_affected="91" subjects_at_risk="102"/>
                <counts group_id="E7" subjects_affected="88" subjects_at_risk="103"/>
                <counts group_id="E8" subjects_affected="83" subjects_at_risk="103"/>
                <counts group_id="E9" subjects_affected="87" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E7" events="7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="103"/>
                <counts group_id="E4" events="10" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E7" events="14" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E8" events="7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E2" events="27" subjects_affected="22" subjects_at_risk="102"/>
                <counts group_id="E3" events="33" subjects_affected="26" subjects_at_risk="103"/>
                <counts group_id="E4" events="25" subjects_affected="18" subjects_at_risk="103"/>
                <counts group_id="E5" events="35" subjects_affected="24" subjects_at_risk="102"/>
                <counts group_id="E6" events="23" subjects_affected="19" subjects_at_risk="102"/>
                <counts group_id="E7" events="34" subjects_affected="29" subjects_at_risk="103"/>
                <counts group_id="E8" events="30" subjects_affected="24" subjects_at_risk="103"/>
                <counts group_id="E9" events="7" subjects_affected="6" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="29" subjects_affected="20" subjects_at_risk="103"/>
                <counts group_id="E2" events="37" subjects_affected="25" subjects_at_risk="102"/>
                <counts group_id="E3" events="60" subjects_affected="35" subjects_at_risk="103"/>
                <counts group_id="E4" events="54" subjects_affected="27" subjects_at_risk="103"/>
                <counts group_id="E5" events="62" subjects_affected="38" subjects_at_risk="102"/>
                <counts group_id="E6" events="52" subjects_affected="28" subjects_at_risk="102"/>
                <counts group_id="E7" events="49" subjects_affected="28" subjects_at_risk="103"/>
                <counts group_id="E8" events="46" subjects_affected="29" subjects_at_risk="103"/>
                <counts group_id="E9" events="23" subjects_affected="16" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="24" subjects_affected="14" subjects_at_risk="103"/>
                <counts group_id="E5" events="17" subjects_affected="14" subjects_at_risk="102"/>
                <counts group_id="E6" events="16" subjects_affected="15" subjects_at_risk="102"/>
                <counts group_id="E7" events="19" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E8" events="13" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E9" events="5" subjects_affected="4" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" events="20" subjects_affected="14" subjects_at_risk="103"/>
                <counts group_id="E4" events="12" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E6" events="21" subjects_affected="17" subjects_at_risk="102"/>
                <counts group_id="E7" events="12" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E8" events="9" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E6" events="10" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E7" events="8" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E6" events="13" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E7" events="13" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E8" events="9" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="41" subjects_affected="32" subjects_at_risk="103"/>
                <counts group_id="E2" events="80" subjects_affected="42" subjects_at_risk="102"/>
                <counts group_id="E3" events="74" subjects_affected="45" subjects_at_risk="103"/>
                <counts group_id="E4" events="69" subjects_affected="43" subjects_at_risk="103"/>
                <counts group_id="E5" events="94" subjects_affected="49" subjects_at_risk="102"/>
                <counts group_id="E6" events="106" subjects_affected="55" subjects_at_risk="102"/>
                <counts group_id="E7" events="97" subjects_affected="50" subjects_at_risk="103"/>
                <counts group_id="E8" events="89" subjects_affected="46" subjects_at_risk="103"/>
                <counts group_id="E9" events="30" subjects_affected="24" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" events="29" subjects_affected="18" subjects_at_risk="102"/>
                <counts group_id="E3" events="41" subjects_affected="24" subjects_at_risk="103"/>
                <counts group_id="E4" events="18" subjects_affected="11" subjects_at_risk="103"/>
                <counts group_id="E5" events="34" subjects_affected="17" subjects_at_risk="102"/>
                <counts group_id="E6" events="32" subjects_affected="21" subjects_at_risk="102"/>
                <counts group_id="E7" events="46" subjects_affected="23" subjects_at_risk="103"/>
                <counts group_id="E8" events="17" subjects_affected="11" subjects_at_risk="103"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Early satiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E5" events="15" subjects_affected="13" subjects_at_risk="102"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E9" events="9" subjects_affected="9" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E4" events="10" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E7" events="8" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E9" events="27" subjects_affected="9" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E9" events="12" subjects_affected="9" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E5" events="11" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E9" events="6" subjects_affected="4" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="14" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" events="9" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E9" events="9" subjects_affected="8" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="16" subjects_at_risk="103"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="102"/>
                <counts group_id="E3" events="24" subjects_affected="19" subjects_at_risk="103"/>
                <counts group_id="E4" events="20" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E5" events="26" subjects_affected="19" subjects_at_risk="102"/>
                <counts group_id="E6" events="18" subjects_affected="16" subjects_at_risk="102"/>
                <counts group_id="E7" events="27" subjects_affected="20" subjects_at_risk="103"/>
                <counts group_id="E8" events="22" subjects_affected="16" subjects_at_risk="103"/>
                <counts group_id="E9" events="26" subjects_affected="16" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="10" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E9" events="8" subjects_affected="8" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E4" events="15" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E5" events="16" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E6" events="11" subjects_affected="10" subjects_at_risk="102"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" events="16" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E9" events="19" subjects_affected="13" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E9" events="11" subjects_affected="5" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E9" events="14" subjects_affected="7" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="102"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E4" events="14" subjects_affected="13" subjects_at_risk="103"/>
                <counts group_id="E5" events="14" subjects_affected="14" subjects_at_risk="102"/>
                <counts group_id="E6" events="21" subjects_affected="18" subjects_at_risk="102"/>
                <counts group_id="E7" events="23" subjects_affected="20" subjects_at_risk="103"/>
                <counts group_id="E8" events="13" subjects_affected="12" subjects_at_risk="103"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E9" events="10" subjects_affected="10" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="102"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="103"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E9" events="11" subjects_affected="10" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="103"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E5" events="11" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E7" events="8" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="103"/>
                <counts group_id="E2" events="20" subjects_affected="15" subjects_at_risk="102"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="103"/>
                <counts group_id="E5" events="31" subjects_affected="20" subjects_at_risk="102"/>
                <counts group_id="E6" events="17" subjects_affected="14" subjects_at_risk="102"/>
                <counts group_id="E7" events="13" subjects_affected="11" subjects_at_risk="103"/>
                <counts group_id="E8" events="22" subjects_affected="15" subjects_at_risk="103"/>
                <counts group_id="E9" events="19" subjects_affected="15" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="103"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="103"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="102"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="102"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="103"/>
                <counts group_id="E9" events="7" subjects_affected="7" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="103"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="103"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="103"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At the end of the trial, one or more scientific publications may be prepared collaboratively by the investigator(s) and Novo Nordisk. Novo Nordisk reserves the right to postpone publication and/or communication for up to 60 days to protect intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Reporting Anchor and Disclosure (1452)</name_or_title>
      <organization>Novo Nordisk A/S</organization>
      <phone>(+1) 866-867-7178</phone>
      <email>clinicaltrials@novonordisk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

